var title_f28_47_29424="UV lesions V";
var content_f28_47_29424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F81159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F81159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Urticarial vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urticarial patches with annular, semiannular, and occasionally concentric formation. Note scattered associated ecchymoses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29424=[""].join("\n");
var outline_f28_47_29424=null;
var title_f28_47_29425="Adenomatoid malform CXR III";
var content_f28_47_29425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic adenomatoid malformation of the left lower lobe in 30-year-old man with recurrent pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A frontal chest radiograph shows a mass-like consolidation involving primarily the superior segment of the left lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29425=[""].join("\n");
var outline_f28_47_29425=null;
var title_f28_47_29426="Tissue Doppler normal LV";
var content_f28_47_29426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Tissue Doppler echocardiographic image of normal left ventricle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tissue Doppler image, obtained from the parastenal long-axis view, shows normal left ventricular systolic function. Panel A shows the color-coded two-dimensional tissue Doppler image; panel B shows the corresponding color-M-mode tissue Doppler image for a single cardiac cycle and panel C is the time-velocity plot of the posterior wall of the color-M-mode tissue Doppler image.",
"    <div class=\"footnotes\">",
"     S: peak systolic velocity; E: peak early diastolic velocity; A: peak atrial velocity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29426=[""].join("\n");
var outline_f28_47_29426=null;
var title_f28_47_29427="Spaso technique for shoulder reduction";
var content_f28_47_29427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spaso technique for shoulder reduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 485px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arm is flexed forward and gentle traction and external rotation forces are applied.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott C Sherman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29427=[""].join("\n");
var outline_f28_47_29427=null;
var title_f28_47_29428="12-lead ECG right anterior septal WPW";
var content_f28_47_29428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) of a right anterior septal accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram from a patient with Wolff-Parkinson-White syndrome during sinus tachycardia show a maximally preexcited QRS complex which has a left bundle branch block pattern and is markedly positive in the inferior leads. The delta wave is isoelectric in leads aVL and V6. These features localize the accessory pathway to the right anterior septum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29428=[""].join("\n");
var outline_f28_47_29428=null;
var title_f28_47_29429="Food allergy symptoms and diagnosis";
var content_f28_47_29429=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/47/29429/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29429/contributors\" id=\"au5677\">",
"       Wesley Burks, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/47/29429/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29429/contributors\" id=\"se917\">",
"       Scott H Sicherer, MD, FAAAAI",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/47/29429/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29429/contributors\" id=\"de2295\">",
"       Elizabeth TePas, MD, MS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?28/47/29429?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      FOOD ALLERGY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Reactions to food are common, and can be divided into two categories, those caused by food allergy and all other reactions. It is important to know the difference between food allergies and other illnesses or symptoms caused by foods because the management of each is different.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Food allergies develop when the body's immune system has an abnormal reaction to one or more proteins in a food. Food allergies can lead to serious or even life-threatening allergic reactions.",
"      </li>",
"      <li>",
"       Other food reactions are not caused by the immune system. These reactions cause unpleasant symptoms and are far more common than food allergies. Examples include lactose intolerance, heartburn (gastroesophageal reflux), bacterial food poisoning, and sensitivity to caffeine, just to name a few.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This topic discusses the signs and symptoms of food allergy and testing that may be recommended to diagnose food allergies. The avoidance of foods in people with food allergies is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"      \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CLASSIC FOOD ALLERGIES",
"     </span>",
"    </p>",
"    <p>",
"     In people with \"classic\" food allergies, allergic antibodies, called IgE, develop in response to proteins in certain foods. When the person is exposed to that protein at a later time (eg, by eating peanuts), binding of the food protein to IgE triggers a release of chemicals, which cause the symptoms of an allergic reaction. This typically occurs quickly, within minutes to two hours after eating.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Sudden-onset symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The symptoms of a food allergy can vary from mild to severe or even life-threatening. It is not always possible to predict how severe symptoms will be based upon the symptoms experienced during a previous reaction. As an example, a person could have mild hives after eating peanuts on one occasion, and then have an anaphylactic reaction after eating peanuts another time. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"      \"Clinical manifestations of food allergy: An overview\"",
"     </a>",
"     .) However, reactions are not necessarily worse after each exposure.",
"    </p>",
"    <p>",
"     The most common sudden-onset symptoms of food allergy include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Skin: Itching, flushing, hives (urticaria, like mosquito bites), or swelling (angioedema)",
"      </li>",
"      <li>",
"       Eyes: Itching, tearing, redness, or swelling of the skin around the eyes",
"      </li>",
"      <li>",
"       Nose and mouth: Sneezing, runny nose, nasal congestion, swelling of the tongue, or a metallic taste",
"      </li>",
"      <li>",
"       Lungs and throat: Difficulty getting air in or out, repeated coughing, chest tightness, wheezing or other sounds of labored breathing, increased mucus production, throat swelling or itching, hoarseness, change in voice, or a sensation of choking",
"      </li>",
"      <li>",
"       Heart and circulation: Dizziness, weakness, fainting, rapid, slow, or irregular heart rate, or low blood pressure",
"      </li>",
"      <li>",
"       Digestive system: Nausea, vomiting, abdominal cramps, or diarrhea",
"      </li>",
"      <li>",
"       Nervous system: Anxiety, confusion, or a sense of impending doom",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Associated conditions",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Anaphylaxis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Generalized anaphylaxis is the most serious type of allergic reaction, and can cause life-threatening signs and symptoms, including difficulty breathing, swelling of the upper throat",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     tongue, a very rapid or irregular heartbeat, low blood pressure, or cardiac arrest (the heart stops beating). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"      \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Generalized anaphylaxis generally begins within 5 to 60 minutes of exposure to a trigger, although rarely, symptoms begin several hours after eating. A person who develops symptoms of anaphylaxis must be treated immediately with an injection of epinephrine. Treatment of anaphylaxis is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"      \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Many different foods can potentially trigger anaphylaxis. In adults, peanuts, tree nuts (eg, walnuts), fish, and shellfish cause most anaphylactic reactions. In children, peanuts and tree nuts are the most common causes of anaphylactic reactions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Allergic rhinitis and conjunctivitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Food allergies can trigger allergic symptoms in the nose, eyes, or throat. However, these symptoms usually occur along with whole-body symptoms, such as hives, difficulty breathing, diarrhea, etc. The most common nose, eye, and throat symptoms including a runny nose, congestion, sneezing, nasal itching, itchy or watery red eyes, or voices changes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Oral allergy syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral allergy syndrome, or pollen-food allergy syndrome, is seen in up to 50 percent of people with allergic rhinitis caused by pollen. In this condition, people who are allergic to a pollen have an allergic reaction after eating certain raw (uncooked) fruits or vegetables. The reaction is immediate and can cause itching, irritation, and mild swelling of the lips, tongue, roof of the mouth, and throat. A list of pollens and foods that cross react is available here (",
"     <a class=\"graphic graphic_figure graphicRef58854 \" href=\"UTD.htm?15/28/15817\">",
"      figure 1",
"     </a>",
"     and",
"     <a class=\"graphic graphic_figure graphicRef57162 \" href=\"UTD.htm?8/10/8352\">",
"      figure 2",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=see_link\">",
"      \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link\">",
"      \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Symptoms of oral allergy syndrome may be more noticeable during the associated pollen season. Symptoms usually resolve within minutes after the person stops eating the food. Most people have only localized symptoms (eg, in the mouth).",
"    </p>",
"    <p>",
"     Less than 10 percent of people have systemic symptoms to fruits and vegetables (eg, vomiting or diarrhea) and 1 to 2 percent of people develop generalized anaphylaxis (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Anaphylaxis'",
"     </a>",
"     above). People with a history of systemic symptoms should carry epinephrine autoinjectors.",
"    </p>",
"    <p>",
"     The reaction does not usually occur if the fruits or vegetables are cooked. Tree nuts and peanuts are an exception to this, meaning that anyone with a history of an oral allergy to nuts should avoid them in all forms (raw, roasted, cooked).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Food dependent exercise-induced anaphylaxis",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are some people who develop an anaphylactic reaction after eating a certain food and then exercising up to four hours later. A reaction can occasionally occur after exercising first and then eating. The particular food does not cause anaphylaxis if the person does not exercise. This is called food dependent exercise-induced anaphylaxis. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=see_link\">",
"      \"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42709?source=see_link\">",
"      \"Exercise-induced anaphylaxis: Management and prognosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The most common foods associated with this condition include wheat, celery, and seafood, although some people react after eating any food and then exercising. Not eating for several hours before exercise can usually prevent this type of reaction.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CONDITIONS THAT MAY BE RELATED TO FOOD ALLERGIES",
"     </span>",
"    </p>",
"    <p>",
"     There are several conditions that may be food related, such as eosinophilic gastrointestinal disorders (eosinophilic esophagitis) and atopic dermatitis (eczema). These are discussed in detail separately. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"      \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=see_link\">",
"      \"Patient information: Atopic dermatitis (eczema) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      NON IgE FOOD ALLERGIES",
"     </span>",
"    </p>",
"    <p>",
"     Food allergies can occur without involving IgE. The symptoms of this type of food allergy are usually slower to develop and longer lasting than those of classic food allergies.",
"    </p>",
"    <p>",
"     The three main types of non IgE food allergies are:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Food protein-induced enterocolitis",
"      </li>",
"      <li>",
"       Food protein-induced proctitis and proctocolitis",
"      </li>",
"      <li>",
"       Celiac disease and dermatitis herpetiformis (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"        \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Most of these conditions cause symptoms of the digestive system, such as vomiting, diarrhea, abdominal pain,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     blood in the stool. Food protein-induced enterocolitis and",
"     <span class=\"nowrap\">",
"      proctitis/proctocolitis",
"     </span>",
"     are more commonly seen in infants. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"      \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      FOOD ALLERGY DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Anyone who has signs or symptoms of a food allergy should see their healthcare provider. Between 20 and 30 percent of people report food allergy in themselves or their children. However, only 6 to 8 percent of children under the age of five and 3 to 4 percent of adults have a true food allergy.",
"    </p>",
"    <p>",
"     Laboratory testing",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     skin testing is often used to confirm the food allergy and determine if avoidance of a particular food is necessary. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"      \"Diagnostic evaluation of food allergy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Medical history",
"     </span>",
"     &nbsp;&mdash;&nbsp;During a medical history, the healthcare provider will ask questions about the person's past allergic reactions:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       What symptoms of food allergy did you have?",
"      </li>",
"      <li>",
"       What particular food do you think provoked the reaction? Have you eaten this food before? Have you reacted before?",
"      </li>",
"      <li>",
"       How much of this food did you eat?",
"      </li>",
"      <li>",
"       What other foods did you eat at that time? Do you know all the ingredients of the food you ate? Include all foods: appetizer, main dish, sauces, dressings, breads, beverages, and side dishes.",
"      </li>",
"      <li>",
"       How was the food prepared? As an example, could the food have been fried in oil used to prepare other foods?",
"      </li>",
"      <li>",
"       Were any of following eaten: peanuts, tree nuts, shellfish, fish, milk, eggs, wheat, or soy?",
"      </li>",
"      <li>",
"       How much time passed between eating the food and the first symptoms?",
"      </li>",
"      <li>",
"       Did you exercise or exert yourself after eating?",
"      </li>",
"      <li>",
"       Did you take any medications, herbs, vitamins, non-prescription medications, or drink any alcohol before or after eating?",
"      </li>",
"      <li>",
"       How was the reaction treated? Did it resolve without treatment or did you take any medications? How long were the medications continued and were there any later symptoms?",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Depending upon the answers to these questions and the physical examination, the healthcare provider may decide to order laboratory testing. In other cases, the provider will refer the person to a specialist (allergist or gastroenterologist) for further evaluation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Allergy testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Testing for food allergies often includes skin testing",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     blood tests. Depending upon the situation, tests may be done to determine if a person is allergic to pollens, insects, latex, and other allergens. However, testing is only recommended if the person is suspected to have an allergy. As an example, if a person had a reaction after eating peanuts, but has never reacted to wheat or eggs and eats them regularly, it is not necessary to test for allergy to wheat or eggs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Skin testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Skin testing involves",
"     <span class=\"nowrap\">",
"      pricking/scratching",
"     </span>",
"     the skin with a tiny probe that is coated with food extract or fresh food. The pricks are usually done on the forearm or upper back after the skin is cleaned with alcohol. The skin prick is not usually painful.",
"    </p>",
"    <p>",
"     Skin testing should only be done by a trained healthcare provider, usually an allergy specialist.",
"    </p>",
"    <p>",
"     Adults and children of any age may have skin testing. The test may result in small hives (like a mosquito bite) at the site of the",
"     <span class=\"nowrap\">",
"      prick/scratch.",
"     </span>",
"     Your allergist evaluates the size of the test results to assist in making a diagnosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests are available to assist doctors in making a diagnosis. Neither the skin test nor the blood test can be depended upon to make a diagnosis without a clinician considering the medical history and other supporting information. Blood tests are widely available and do not require an allergy specialist to perform the test. However, consultation with an allergy specialist may be recommended to interpret the results of the test.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Elimination diets",
"     </span>",
"     &nbsp;&mdash;&nbsp;An elimination diet is a specially designed diet that eliminates one or more foods or groups of food from a person's diet for a period of time. The food is then added back to determine if signs or symptoms of a food allergy develop.",
"    </p>",
"    <p>",
"     An elimination diet may be recommended as part of the process of determining if a person has food allergies. An allergist or dietitian must be involved in designing an elimination diet because avoiding entire groups of foods (eg, milk) could potentially lead to malnutrition, especially in infants and children. An elimination diet, by itself, does not often lead to the diagnosis of food allergy.",
"    </p>",
"    <p>",
"     During an elimination diet, it is important to read food labels carefully. In the United States, the Food Allergen Labeling and Consumer Protection Act mandates that nutritional labels on food packages plainly identify eight specified food allergen sources (milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, and soy), although other foods may still appear under multiple names. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"      \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In addition, patients must understand that \"substitute\" foods, which reduce or eliminate fat or other components of a food, still contain the allergenic proteins. As an example, some egg substitutes (which are lower in cholesterol) still contain egg white proteins.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Food diary",
"     </span>",
"     &nbsp;&mdash;&nbsp;A healthcare provider may request that a person keep a complete record of everything they eat over a period of time, including all foods, drinks, condiments, and candies. A table to record this information is available here (",
"     <a class=\"graphic graphic_figure graphicRef58605 \" href=\"UTD.htm?26/37/27231\">",
"      figure 3",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Food challenges",
"     </span>",
"     &nbsp;&mdash;&nbsp;If it is not clear if a person has a food allergy, based upon their medical history and allergy testing, he or she may be offered a medically supervised gradual feeding or food challenge. A food challenge may also be recommended if there is reason to believe that the food allergy has resolved. A food challenge is done by giving the person a tiny amount of the potentially allergenic food to eat. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"      \"Oral food challenges for diagnosis and management of food allergies\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     After the person is given the first sample of food,",
"     <span class=\"nowrap\">",
"      he/she",
"     </span>",
"     is observed for 10 to 15 minutes. If there is no reaction, a slightly larger amount of the food is given. This is continued for approximately 90 minutes or more. If the person develops signs or symptoms of an allergic reaction, the food challenge is immediately stopped.",
"    </p>",
"    <p>",
"     Food challenges should only be performed in a setting where the personnel and equipment needed to treat anaphylaxis are available; this can be an office or hospital setting.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Preparing for the food challenge &mdash; It is important to prepare for a food challenge by not eating or drinking for two hours before the test, and certain medications may need to be stopped days or weeks before. The person should bring their epinephrine autoinjector to the food challenge in case they develop a delayed allergic reaction on the way home.",
"      </li>",
"      <li>",
"       If there is no reaction during the food challenge &mdash; If the person does not have any signs of an allergic reaction during the food challenge,",
"       <span class=\"nowrap\">",
"        he/she",
"       </span>",
"       probably does not have an allergy to the tested food. However, the person may have allergies to other foods, so it is important to understand",
"       <span class=\"nowrap\">",
"        when/if",
"       </span>",
"       foods should continue to be avoided.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     It is sometimes difficult to know if a reaction is caused by a true food allergy or a food intolerance. Anyone who has one or more of the following symptoms after eating should seek medical care:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Nausea or vomiting",
"      </li>",
"      <li>",
"       Cramping, abdominal pain, or diarrhea, especially if there is blood or mucus in the stool",
"      </li>",
"      <li>",
"       Itching or raised red welts on the skin",
"      </li>",
"      <li>",
"       Flushed (reddened, warm) skin",
"      </li>",
"      <li>",
"       Swelling of the lips, mouth, face, or throat",
"      </li>",
"      <li>",
"       Wheezing, coughing, or difficulty breathing",
"      </li>",
"      <li>",
"       Lightheadedness or passing out",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H201\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H253037\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=see_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/59/7091?source=see_link\">",
"      Patient information: Starting solid foods with babies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/26/11684?source=see_link\">",
"      Patient information: Lactose intolerance (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=see_link\">",
"      Patient information: Angioedema (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/54/39778?source=see_link\">",
"      Patient information: Eosinophilic esophagitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42370?source=see_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=see_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H253052\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=see_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=see_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=see_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link\">",
"      Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3705?source=see_link\">",
"      Food allergy in schools and camps",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44057?source=see_link\">",
"      Future therapies for food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20119?source=see_link\">",
"      Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38776?source=see_link\">",
"      Respiratory manifestations of food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38457?source=see_link\">",
"      Peanut, tree nut, and seed allergy: Clinical features",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16346?source=see_link\">",
"      Seafood allergies: Fish and shellfish",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29640?source=see_link\">",
"      Milk allergy: Clinical features and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33944?source=see_link\">",
"      Egg allergy: Clinical features and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=see_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33625?source=see_link\">",
"      Unique aspects of anaphylaxis in infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Medline Plus",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/foodallergy.html\">",
"        www.nlm.nih.gov/medlineplus/foodallergy.html",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       American Academy of Allergy Asthma and Immunology",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aaaai.org/patients.stm\">",
"        www.aaaai.org/patients.stm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Food Allergy and Anaphylaxis Network",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.foodallergy.org/\">",
"        www.foodallergy.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Allergy, Asthma, and Immunology",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acaai.org/\">",
"        www.acaai.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Allergy and Infectious Disease",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niaid.nih.gov/topics/foodAllergy/clinical/Pages/patients.aspx\">",
"        file://www.niaid.nih.gov/topics/foodAllergy/clinical/Pages/patients.aspx",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Food Allergy Initiative",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.faiusa.org/\">",
"        www.faiusa.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Asthma and Allergy Foundation of America",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aafa.org/display.cfm?id=9&amp;sub=20\">",
"        www.aafa.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       US Food and Drug Administration",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.fda.gov/Food/ResourcesForYou/Consumers/ucm079311.htm\">",
"        www.fda.gov/Food/ResourcesForYou/Consumers/ucm079311.htm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       US Department of Health and Human Services",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.healthfinder.gov/scripts/SearchContext.asp?topic=320&amp;section=5&amp;refine=1\">",
"        www.healthfinder.gov/scripts/SearchContext.asp?topic=320&amp;section=5&amp;refine=1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       US Center for Disease Control and Prevention",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cdc.gov/healthyyouth/foodallergies/\">",
"        www.cdc.gov/healthyyouth/foodallergies/",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?28/47/29429/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?28/47/29429?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29429/abstract/1\">",
"      Sicherer SH, Sampson HA. 9. Food allergy. J Allergy Clin Immunol 2006; 117:S470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29429/abstract/2\">",
"      Moneret-Vautrin DA, Morisset M. Adult food allergy. Curr Allergy Asthma Rep 2005; 5:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29429/abstract/3\">",
"      Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick testing in children with food allergy. Pediatr Allergy Immunol 2004; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29429/abstract/4\">",
"      American College of Allergy, Asthma, &amp; Immunology. Food allergy: a practice parameter. Ann Allergy Asthma Immunol 2006; 96:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29429/abstract/5\">",
"      Sicherer SH, Teuber S, Adverse Reactions to Foods Committee. Current approach to the diagnosis and management of adverse reactions to foods. J Allergy Clin Immunol 2004; 114:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29429/abstract/6\">",
"      NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f28_47_29429=[""].join("\n");
var outline_f28_47_29429=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           FOOD ALLERGY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CLASSIC FOOD ALLERGIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CONDITIONS THAT MAY BE RELATED TO FOOD ALLERGIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           NON IgE FOOD ALLERGIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           FOOD ALLERGY DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/28/15817\" title=\"figure 1\">",
"           Pollen-food cross reactivity PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8352\" title=\"figure 2\">",
"           Related food allergies PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/37/27231\" title=\"figure 3\">",
"           Diet diary PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f28_47_29430="Atypical pneumothorax PA";
var content_f28_47_29430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1088px;\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of an atypical pneumothorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left inferolateral atypical pneumothorax in patient with emphysema and pleural adhesions. Left panel: Chest radiograph shows left basilar collection of pleural gas with concave visceral pleural edge toward the chest wall. At first glance, this resembles a bulla. Right panel: After drainage of the pneumothorax, no evidence of a bulla is seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29430=[""].join("\n");
var outline_f28_47_29430=null;
var title_f28_47_29431="Experimental systemic therapy of metastatic bladder cancer";
var content_f28_47_29431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Experimental systemic therapy of metastatic bladder cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/47/29431/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29431/contributors\">",
"     Randall E Millikan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/47/29431/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29431/contributors\">",
"     Derek Raghavan, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/47/29431/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29431/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/47/29431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard first-line therapy for advanced urothelial (transitional cell) carcinoma currently is either a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (M-VAC) or the doublet",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and cisplatin. These regimens produce high response rates and prolong survival; however, most patients ultimately die of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Unfortunately, despite the addition of multiple new active agents (taxanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    , gemcitabine), no regimen has produced better results than the dose-dense version of M-VAC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, many patients are not candidates for cisplatin-based chemotherapy because of renal insufficiency or poor performance status, and they have even shorter survival.",
"   </p>",
"   <p>",
"    New strategies for using angiogenesis inhibitors, molecularly targeted approaches, and immunotherapy, are reviewed here. The results with current regimens in both the first-line and second-line setting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANGIOGENESIS INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signaling though the vascular endothelial growth factor (VEGF) pathway is thought to play a critical role in the growth and progression of urothelial carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Microvessel density, a histologic measure of tumor angiogenesis, is significantly associated with disease-free and overall survival in patients with invasive transitional cell carcinomas of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/5\">",
"     5",
"    </a>",
"    ]. Baseline expression of vascular endothelial growth factor (VEGF) by the tumor has been correlated with survival in patients with locally advanced disease treated with M-VAC or other",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy in at least two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations have led to several approaches to targeting the VEGF pathway in the clinic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blockade of VEGF signaling by means of the humanized monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    enhances the activity of cytotoxic therapy in metastatic colon and lung cancer. This may be a general effect that is mediated by reduced intratumoral pressure, thus allowing greater exposure to chemotherapy. Bevacizumab is currently being evaluated in several clinical studies, in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , both in patients with metastatic disease and as a neoadjuvant.",
"   </p>",
"   <p>",
"    In a multicenter phase II study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    in 43 patients as first line therapy for metastatic urothelial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/8\">",
"     8",
"    </a>",
"    ]. Partial or complete responses were seen in 8 and 23 patients, respectively, for an overall 72 percent response rate. At a median follow-up of 27 months, the median progression-free and overall survival durations were 8 and 19 months, respectively. These results are not inconsistent with earlier reports using gemcitabine plus cisplatin. A cooperative group, phase III trial currently is in progress to assess the role of bevacizumab with this chemotherapy regimen (NCT00942331) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Aflibercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37312?source=see_link\">",
"     Aflibercept",
"    </a>",
"    (also known as the VEGF trap) is a soluble recombinant receptor for VEGF. A phase II study using aflibercept as a single agent in patients with metastatic or recurrent urothelial cancer has completed enrollment, but results are not yet available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    is a first-generation tyrosine kinase inhibitor with biologically relevant activity against many different tyrosine kinase receptors, including VEGF receptor-1. Whether sunitinib is active in these patients is not clear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II study using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      in 45 patients with relapsed or refractory urothelial carcinoma, partial responses were seen in four of 77 cases (5 percent) and stable disease was observed in 33 patients (43 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At the 2012 American Society of Clinical Oncology annual meeting, the results of a randomized phase II trial involving 54 patients (without evidence of disease progression following chemotherapy) were presented [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients were treated with maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      versus placebo. Compared to placebo, sunitinib resulted in a higher proportion of patients progression-free at six months (81 versus 75 percent) and a longer time to progression (median, 5 versus 3 months), although neither results was statistically significant. Sunitinib resulted in a higher rate of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities, including diarrhea (15 versus 0 percent), fatigue (15 versus 4 percent), thrombocytopenia (15 versus 8 percent), and hypertension (12 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23985242\">",
"    <span class=\"h1\">",
"     MOLECULARLY TARGETED THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     EGFR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal urothelium is a mitotically quiescent epithelial layer despite being normally exposed to elevated concentrations of growth factors present in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the urothelium is capable of a rapid proliferative response in response to injury, which has been shown to be mediated at least in part by epidermal growth factor receptor (EGFR) signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Members of the EGFR family (ie, HER-1) are overexpressed in urothelial carcinomas. Their overexpression is associated with features of poor prognosis, such as high tumor stage and high grade [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], suggesting that the malignant urothelium usurps this pathway to stimulate proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/16\">",
"     16",
"    </a>",
"    ]. This concept is further supported by the fact that EGFR inhibitors can inhibit the growth of bladder cancer cells in culture and in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In addition, EGFR signaling has been implicated in the regulation of angiogenesis, invasion, and metastasis as well as cell survival in tumor models [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations have provided the rationale for clinically testing inhibition of this pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gefitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase II of single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    in 31 patients with metastatic disease who had progressed after one chemotherapeutic regimen showed minimal activity, with only one partial response and an estimated median survival of three months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several subsequent studies have combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    with cytotoxic chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial study combined",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      with a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      using a fixed dose-rate of gemcitabine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/21\">",
"       21",
"      </a>",
"      ]. This study was discontinued after enrolling 27 of the planned 50 patients because of excess toxicity.",
"     </li>",
"     <li>",
"      An overall response rate of 51 percent was seen in a study of 54 evaluable patients, in which the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      was given using 30 minute dosing of gemcitabine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/22\">",
"       22",
"      </a>",
"      ]. The median overall survival was 15 months. These results were consistence with what would be expected for gemcitabine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      A randomized phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      with or without concomitant or sequential",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      has been completed but not yet reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In view of the antiangiogenic effects of HER-1 blockade, a role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    as a maintenance therapy after optimal response to systemic chemotherapy has been investigated. In this trial, patients at maximal response to front-line chemotherapy were randomized to either gefitinib plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    or docetaxel alone. The trial has completed accrual but results are not yet available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach to blocking the EGFR pathway uses",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , a monoclonal antibody targeted against the EGFR receptor. A multicenter phase II trial is assessing the role of cetuximab in patients with advanced or metastatic urothelial cancer. Patients are randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    with or without",
"    <span class=\"nowrap\">",
"     cetuximab.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;HER2/neu",
"    is overexpressed in many urothelial cancers, providing the basis for its clinical investigation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       Trastuzumab",
"      </a>",
"      was combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      in a phase II study of patients with advanced urothelial carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/23\">",
"       23",
"      </a>",
"      ]. Patients had",
"      <span class=\"nowrap\">",
"       HER-2/neu",
"      </span>",
"      overexpression proven by tissue IHC or FISH, or by an elevated serum",
"      <span class=\"nowrap\">",
"       HER-2/neu",
"      </span>",
"      extracellular domain. Overall, 57 of 109 patients (52 percent) who were screened met this criterion and of these, 44 were eligible for treatment. Interestingly, only 15 of the 57 were found to be FISH positive, indicating that gene amplification is not a common mechanism of",
"      <span class=\"nowrap\">",
"       HER2/neu",
"      </span>",
"      overexpression in bladder cancer. The overall response rate was 70 percent, the median time to progression was nine months and the median survival 14 months. These results are similar to what would be expected for this chemotherapy regimen without trastuzumab. Thus, a large effect is unlikely, although a more definitive comparison will be required to determine whether this did make a small contribution.",
"     </li>",
"     <li>",
"      The CALGB has completed a phase II study of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      in patients with advanced or metastatic urothelial carcinomas, but results have not yet been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Erlotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     Erlotinib",
"    </a>",
"    has some activity against both HER-1 and HER-2. Ongoing studies are examining the effect of neoadjuvant and adjuvant erlotinib in patients undergoing radical cystectomy for muscle-invasive bladder cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lapatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    is an orally active tyrosine kinase inhibitor that blocks both HER-2 and the epidermal growth factor receptor. Lapatinib is being investigated as first-line therapy for patients with urothelial cancer in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    . Lapatinib was also studied in bladder cancer patients who had progressed after chemotherapy and whose tumors expressed ErbB2. Results are pending.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Multitargeted TK inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several multitargeted tyrosine kinase (TK) inhibitors are also being evaluated for the treatment of patients with urothelial cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    interacts with many receptor TKs, including raf-kinase and the VEGF receptor TK. A single-agent phase II study of sorafenib in the second-line setting observed no responses among 22 evaluable patients, and the median time to progression was 2.2 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/24\">",
"     24",
"    </a>",
"    ]. A preliminary report of a phase II trial in previously untreated patients also reported no objective responses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/25\">",
"     25",
"    </a>",
"    ]. Combination studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and gemcitabine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    is a second-generation multitargeted TK inhibitor of the VEGFR-1, 2 and 3, platelet-derived growth factor receptors and c-kit that shows promising activity in this disease. This was demonstrated in a phase II study of 41 patients who had progressed despite one or more",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy regimens; all patients were treated with pazopanib (800 mg orally) on a daily basis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/26\">",
"     26",
"    </a>",
"    ]. The overall response rate was 17 percent (95 % CI 7 to 32 percent), all of which were partial responses. Serious (grade 3) toxicities occurred in less than 10 percent of study participants but included hypertension, fatigue, and the development of gastrointestinal or vaginal fistulas. There was one death on study related to treatment, which resulted from the development of a duodenal fistula felt secondary to tumor response in a bulky tumor mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vandetanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    is a small molecule that inhibits both VEGFR-2 and EGFR TK activity. In a randomized trial, the addition of vandetanib to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    did not improve the objective response rate, progression-free survival, or overall survival compared with docetaxel alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/27\">",
"     27",
"    </a>",
"    ]. A similar failure to improve outcome when combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    was reported in the context of lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     IMMUNE MODULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy has been an appealing concept for the treatment of cancer for more than a century. The exquisite specificity of the human immune system against infectious organisms is a tantalizing prospect for targeting cancer.",
"   </p>",
"   <p>",
"    Early preclinical studies in mice demonstrated regression of tumors when the mice were injected with Bacillus Calmette-Guerin (BCG) prior to transplantation of tumor cells as compared to mice that did not receive BCG treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/29\">",
"     29",
"    </a>",
"    ]. This observation formed the conceptual foundation used to develop the first standard clinical practice using nonspecific immunotherapy: intravesical administration of BCG for the treatment of superficial bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Intravesical BCG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the precise mechanism of action of BCG therapy is not fully understood, the success of intravesical BCG in treating superficial bladder cancer has stimulated further investigations of immunotherapy for the systemic treatment of bladder cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tumor antigens have been studied as possible targets for vaccine development.",
"   </p>",
"   <p>",
"    As an example, investigation of expression of the cancer-testis (CT) antigens NY-ESO-1 and LAGE-1 in specimens from patients with urothelial carcinoma demonstrated that one or both of these antigens were expressed in 39 of 82 high-grade tumors (48 percent) and in 3 of 22 low-grade cancers (14 percent). An expanded panel of nine CT antigens (NY-ESO-1, LAGE-1, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, CT7, CT10, and GAGE) was evaluated in a cohort of 94 high-grade urothelial cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/30\">",
"     30",
"    </a>",
"    ]. At least one cancer-testis (CT) antigen was expressed in 77 percent of samples and 61 percent expressed more than one CT antigen.",
"   </p>",
"   <p>",
"    NY-ESO-1 is a highly immunogenic member of the CT antigen family. Up to 50 percent of patients with tumors expressing NY-ESO-1 develop spontaneous humoral and cellular immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/31\">",
"     31",
"    </a>",
"    ]. Furthermore, the tumor antigen NY-ESO-1 occurs in approximately 30 to 40 percent of muscle-invasive tumors and CD8-expressing T cells can recognize the NY-ESO-1 antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/32\">",
"     32",
"    </a>",
"    ]. Tumor-infiltrating CD8 expressing T cells are predictive of survival in patients with urothelial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/33\">",
"     33",
"    </a>",
"    ], further supporting the rationale behind vaccine development.",
"   </p>",
"   <p>",
"    Based on these results, a clinical study using a NY-ESO-1 vaccine was conducted in patients with urothelial cancer whose tumors expressed the NY-ESO-1 antigen and who received vaccination in the adjuvant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/34\">",
"     34",
"    </a>",
"    ]. Six patients were enrolled, and all six developed antigen-specific immune responses, consisting of antibody or CD8 or CD4 T cell responses specific for NY-ESO-1. The vaccine, which was given in combination with intradermal BCG and GM-CSF, was well tolerated.",
"   </p>",
"   <p>",
"    Other trials of urothelial cancer vaccines that are already completed include a study in which the CT antigen MAGE-A3 was used as a peptide vaccine loaded onto autologous dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/35\">",
"     35",
"    </a>",
"    ] and another study of a recombinant MAGE-A3 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/36\">",
"     36",
"    </a>",
"    ]. Both trials demonstrated safety of vaccination and provided some evidence of immune and tumor responses, but there is as yet no demonstration of clinical efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immune cell signaling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best-characterized inhibitory cell signaling system consists of the interactions between the cytotoxic lymphocyte antigen-4 (CTLA-4) and the B7 family of membrane proteins. Activation of naive T cells is based on the interaction of B7 family members with CD28. The B7-CD28 positive costimulatory process is opposed by the B7-CTLA-4 inhibitory interaction.",
"   </p>",
"   <p>",
"    Anti-CTLA-4 antibodies have been used to overcome the inhibitory B7-CTLA-4 signal. This approach has shown promise for the immunologic treatment of cancer. Transient or abrupt disengagement of an ongoing, therapeutically relevant T cell response in the face of progressive tumor growth may shift the balance from induction of tumor immunity to tumor tolerance. This provides the rationale to hypothesize that CTLA-4 blockade may sustain the biological activity of in vivo-primed T cells.",
"   </p>",
"   <p>",
"    The administration of anti-CTLA-4 monoclonal antibody as monotherapy in preclinical models has been demonstrated to potentiate antitumor activity in tumor-bearing hosts, to induce tumor rejection and provide long lasting immunity to rechallenge [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/37\">",
"     37",
"    </a>",
"    ]. In combination with appropriate vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/38\">",
"     38",
"    </a>",
"    ], anti-CTLA-4 therapy has also been shown to be effective against poorly immunogenic tumors in model systems.",
"   </p>",
"   <p>",
"    In an ongoing clinical trial, patients with bladder cancer receive anti-CTLA-4 antibody for two doses, given three weeks apart, prior to undergoing radical cystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/39\">",
"     39",
"    </a>",
"    ]. The primary endpoint of the trial is safety and the secondary endpoint consists of identifying immunologic markers in peripheral blood and tumor samples that correlate with drug administration, which may potentially be used in future trials in the metastatic disease setting for correlation with clinical outcome. Clearly, a study of an antigen specific vaccine in combination with anti-CTLA-4 antibody is of substantial interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23985354\">",
"    <span class=\"h1\">",
"     DRUG DISCOVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the promise of angiogenesis inhibitors and the expanding field of molecularly targeted agents, the identification of novel chemotherapeutic agents remains a priority for advancing treatment options for these patients. A novel method for predicting drug sensitivity is coexpression extrapolation (COXEN) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29431/abstract/40\">",
"     40",
"    </a>",
"    ]. This approach utilizes gene expression in a set of cell lines (eg, NCI-60 panel) with known sensitivity to various chemotherapy agents. Expression markers strongly associated with either sensitivity or resistance to a particular agent are identified and that \"signature\" is extrapolated to an unknown cell line or a patient sample. Despite its promise, there are no published reports of using COXEN with tissues from bladder cancer patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approaches that appear to be particularly promising have focused on the vascular endothelial growth factor pathway, epidermal growth factor receptor pathway, and the use of multitargeted tyrosine kinase inhibitors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Angiogenesis inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23985242\">",
"       'Molecularly targeted therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Multitargeted TK inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary efforts at immunotherapy include the development of tumor vaccines, against antigens such as NY-ESO-1 or the use of antibodies directed against CTLA-4. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Immune modulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whenever possible, patients with advanced urothelial cancer should be offered clinical studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791450750\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Drs. Ana Aparicio and Padmanee Sharma, who contributed to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/1\">",
"      Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/2\">",
"      von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/3\">",
"      Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/4\">",
"      Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer 2006; 5:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/5\">",
"      Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995; 87:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/6\">",
"      Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004; 171:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/7\">",
"      Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000; 6:4866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/8\">",
"      Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 2011; 29:1525.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on February 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/10\">",
"      Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010; 28:1373.",
"     </a>",
"    </li>",
"    <li>",
"     Gricas P, Nanus DM, Stadler WM, et al. Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). J Clin Oncol 30, 2012 (suppl 5; abstr 265).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/12\">",
"      Limas C. Proliferative state of the urothelium with benign and atypical changes. Correlation with transferrin and epidermal growth factor receptors and blood group antigens. J Pathol 1993; 171:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/13\">",
"      Daher A, de Boer WI, El-Marjou A, et al. Epidermal growth factor receptor regulates normal urothelial regeneration. Lab Invest 2003; 83:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/14\">",
"      Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985; 1:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/15\">",
"      Berger MS, Greenfield C, Gullick WJ, et al. Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer 1987; 56:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/16\">",
"      Cheng J, Huang H, Zhang ZT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002; 62:4157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/17\">",
"      Dinney CP, Parker C, Dong Z, et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res 1997; 3:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/18\">",
"      Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/19\">",
"      Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003; 46 Suppl:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/20\">",
"      Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010; 105:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/21\">",
"      Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 2008; 101:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/22\">",
"      Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009; 20:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/23\">",
"      Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/24\">",
"      Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115:4090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/25\">",
"      Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 2011; 29:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/26\">",
"      Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 2012; 13:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/27\">",
"      Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012; 30:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/28\">",
"      Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:5407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/29\">",
"      OLD LJ, CLARKE DA, BENACERRAF B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 1959; 184(Suppl 5):291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/30\">",
"      Sharma P, Shen Y, Wen S, et al. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006; 12:5442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/31\">",
"      Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/32\">",
"      Sharma P, Gnjatic S, Jungbluth AA, et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 2003; 3:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/33\">",
"      Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007; 104:3967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/34\">",
"      Sharma P, Bajorin DF, Jungbluth AA, et al. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008; 31:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/35\">",
"      Nishiyama T, Tachibana M, Horiguchi Y, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 2001; 7:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/36\">",
"      Marchand M, Punt CJ, Aamdal S, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003; 39:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/37\">",
"      Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/38\">",
"      van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/39\">",
"      Sun J, Schiffman J, Raghunath A, et al. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 2008; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29431/abstract/40\">",
"      Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007; 104:13086.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2975 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29431=[""].join("\n");
var outline_f28_47_29431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANGIOGENESIS INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Aflibercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23985242\">",
"      MOLECULARLY TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EGFR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gefitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cetuximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Erlotinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lapatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Multitargeted TK inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vandetanib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      IMMUNE MODULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immune cell signaling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23985354\">",
"      DRUG DISCOVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H791450750\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=related_link\">",
"      Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_47_29432="Preparation for pediatric procedural sedation outside of the operating room";
var content_f28_47_29432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preparation for pediatric procedural sedation outside of the operating room",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/47/29432/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29432/contributors\">",
"     Joseph P Cravero, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29432/contributors\">",
"     Deborah C Hsu, MD, MEd",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/47/29432/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29432/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29432/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/47/29432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29432/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/47/29432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1560650\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of diagnostic and therapeutic procedures in children is safer and more likely to be successful when the patient does not move and when any associated pain and anxiety are effectively controlled. Pharmacologic and nonpharmacologic interventions that consider the child's age, developmental status, and the clinical circumstances are often required to meet these goals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, attention to the treatment of pain and anxiety associated with the child's condition is a requisite of acceptable and compassionate patient care. Specific issues related to the importance of addressing pain and anxiety in emergency medical systems has been emphasized in a clinical report from the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased availability of short-acting sedatives along with accurate noninvasive monitoring has enabled effective and safe management of sedation and analgesia outside the operating room [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/3\">",
"     3",
"    </a>",
"    ]. Procedural sedation is an evolving field practiced by a diverse group of practitioners in an expanding variety of clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/4\">",
"     4",
"    </a>",
"    ]. Among the challenges that must be addressed, the development of standardized definitions of outcomes, particularly with respect to what constitutes satisfactory fasting for sedation is essential. In addition, there remains a number of guidelines for sedation promulgated by various specialty societies. Unified multidisciplinary guidelines would encourage consistent care across specialties and sedation settings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the preparation for pediatric procedural sedation, regardless of setting, including assessment of American Society of Anesthesiologists classification and fasting status, and assurance of necessary personnel, equipment, and monitoring.",
"   </p>",
"   <p>",
"    A discussion of the nonpharmacologic and pharmacologic interventions for pediatric procedural sedation as well as pediatric airway management and rapid sequence intubation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560678\">",
"    <span class=\"h1\">",
"     GOALS OF SEDATION AND ANALGESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goals of sedation and analgesia for painful procedures are to [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintain patient safety and welfare",
"     </li>",
"     <li>",
"      Minimize physical pain and discomfort",
"     </li>",
"     <li>",
"      Control anxiety, minimize psychological trauma, maximize amnesia",
"     </li>",
"     <li>",
"      Control behavior movement to allow safe performance of procedures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician must determine the appropriate level of sedation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    analgesia required for a particular procedure. In addition to medications, non-pharmacological interventions, such as verbal reassurance, distraction techniques, and hypnosis may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1684879#H1684879\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Nonpharmacologic interventions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H7977200#H7977200\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560685\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Procedural sedation&rdquo; is a term used by a variety of practitioners that describes the broad spectrum of interventions that can be used to alter patient response so that tests and procedures can be accomplished.",
"   </p>",
"   <p>",
"    &ldquo;Conscious sedation&rdquo; is an older term that is sometimes used to refer to this area of practice. Because effective sedation usually impairs consciousness, this term has been abandoned by the American Academy of Pediatrics and the American Society of Anesthesiologists when referring to sedation states.",
"   </p>",
"   <p>",
"    The progression from mild sedation to general anesthesia is a continuum and patients can easily move from one &ldquo;level&rdquo; of sedation to another. Attempts to codify sedation &ldquo;states&rdquo; have evolved over the last 30 years. The American Academy of Pediatrics, the American Society of Anesthesiologists, the American Academy of Pediatric Dentists, and the Joint Commission use the following definitions to describe the depth of sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/4,6-8\">",
"     4,6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Analgesia",
"      </strong>",
"      &ndash; Relief of pain without intentionally producing a sedated state. Altered mental status may be a secondary effect of medications administered for analgesia.",
"     </li>",
"     <li>",
"      <strong>",
"       Minimal sedation",
"      </strong>",
"      &ndash; The patient responds normally to verbal commands. Cognitive function and coordination may be impaired, but ventilatory and cardiovascular function is unaffected.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate",
"       <span class=\"nowrap\">",
"        sedation/analgesia",
"       </span>",
"      </strong>",
"      &ndash; The patient responds purposefully to verbal commands either alone or accompanied by light touch. Maintains airway and adequate ventilation without intervention. Cardiovascular function is maintained.",
"     </li>",
"     <li>",
"      <strong>",
"       Deep",
"       <span class=\"nowrap\">",
"        sedation/analgesia",
"       </span>",
"      </strong>",
"      &ndash; The patient cannot be easily aroused, but responds purposefully to noxious stimulation. May require assistance to maintain airway and adequate ventilation. Cardiovascular function is usually maintained.",
"     </li>",
"     <li>",
"      <strong>",
"       General anesthesia",
"      </strong>",
"      &ndash; The patient cannot be aroused. Often requires assistance to maintain airway and positive pressure ventilation. Cardiovascular function may be impaired.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines and regulatory agencies also use these sedation depth descriptions to describe the relative risk state for a given patient, thus the level of provider care and monitoring varies with the sedation level [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/4\">",
"     4",
"    </a>",
"    ]. As a general rule, the Joint Commission recommends that providers have the capability of managing patients one level deeper than the target depth.",
"   </p>",
"   <p>",
"    Members of the American College of Emergency Physicians have suggested the following definition for sedation induced by",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dissociative sedation",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      sedation is characterized by a dissociative trance-like, cataleptic state in which the patient experiences profound analgesia and amnesia, but retains airway protective reflexes, spontaneous respirations, and cardiopulmonary stability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts have suggested that this state should be considered distinct from the sedation spectrum outlined above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/9\">",
"     9",
"    </a>",
"    ]. While accurate and useful, this categorization of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    sedation is not part of the standard definitions of sedation in other medical specialties or regulatory bodies described above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=see_link&amp;anchor=H2152498#H2152498\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Ketamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560692\">",
"    <span class=\"h1\">",
"     PRE-SEDATION EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be evaluated prior to the procedure for their suitability for sedation. The history should include allergies, use of medications, diseases and hospitalizations, previous exposure to sedation or general anesthesia, relevant family history, and the time and content of their last oral intake. Physical examination should include auscultation of the heart and lungs and evaluation of the neck and airway for conditions that might interfere with endotracheal intubation or resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183724\">",
"    <span class=\"h2\">",
"     Focused medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should obtain a medical history that identifies potential sedation risks, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Major medical illnesses, especially those affecting the respiratory, cardiovascular, and neurologic systems",
"     </li>",
"     <li>",
"      History of snoring or central or obstructive sleep apnea",
"     </li>",
"     <li>",
"      History of prior sedation or general anesthesia including any prior complications",
"     </li>",
"     <li>",
"      Family history of an adverse reaction to sedation, analgesia, or general anesthesia",
"     </li>",
"     <li>",
"      Pregnancy status, if applicable",
"     </li>",
"     <li>",
"      Drug or food allergies",
"     </li>",
"     <li>",
"      Current medications, including prescription, over-the-counter, and herbal preparations",
"     </li>",
"     <li>",
"      Recent illicit drug use",
"     </li>",
"     <li>",
"      Review of systems that evaluate cardiac, pulmonary, renal, bowel, and hepatic function",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11047750\">",
"    <span class=\"h2\">",
"     Fasting and aspiration risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of fasting prior to sedation is to reduce the risk of pulmonary aspiration of gastric contents. The use of prolonged fasting intervals prior to sedation for urgent or emergent procedures remains an area of practice difference among clinicians providing sedation and anesthesia for children. Evidence regarding the optimum duration of fasting required to reduce the risk of aspiration during pediatric procedural sedation is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspiration of gastric contents during anesthesia or sedation is a rare, though much feared complication. Among adults, the estimated incidence of perioperative aspiration is approximately 1 in 7000 patients with a mortality of 1 in 99,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Patients undergoing emergency procedures that require sedation are thought to be at increased risk of aspiration because fasting has often not occurred and the procedure cannot be delayed. In addition, the underlying condition (eg, pyloric stenosis, duodenal hematoma, surgical abdomen, history of severe gastroesophageal reflux) and severity of illness (eg, major trauma) may also increase aspiration risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Aspiration does not always cause harm. However, aspirated gastric contents above a critical volume and acidity can cause severe respiratory and systemic consequences, including death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/16\">",
"     16",
"    </a>",
"    ]. The importance of fasting for preventing aspiration during procedural sedation remains unclear, and there is no clear relationship reported between the duration of fasting prior to procedural sedation and the likelihood of aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. Problems, such as major trauma, can decrease the rapidity of gastric emptying, thus making the usual fasting intervals less reliably protective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183696\">",
"    <span class=\"h3\">",
"     Elective procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and the American Society of Anesthesiologists (ASA) suggest that children, undergoing sedation for scheduled",
"    <strong>",
"     elective",
"    </strong>",
"    procedures outside of the operating room, fast as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two hours after receiving clear liquids",
"     </li>",
"     <li>",
"      Four hours after breast feeding",
"     </li>",
"     <li>",
"      Six hours after ingesting solid foods, formula, or milk other than human milk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these intervals, the impact of time since ingestion of clear liquids has been best studied. As an example, in a systematic review of 23 randomized trials of preoperative fasting regimens for children at normal risk for aspiration during anesthesia, fasting for two hours preoperatively had no clinically important difference in intraoperative gastric volume or pH and provided greater patient comfort when compared to six hours of complete fasting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/22\">",
"     22",
"    </a>",
"    ]. Although fasting to reduce the risk of aspiration during sedation or elective surgery makes intuitive sense, there is little evidence that this approach actually prevents aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/19,20,23-25\">",
"     19,20,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The (ASA) guidelines have been provided in a consensus statement and are based upon expert opinion and, to a lesser extent extrapolated from general anesthesia data, in which aspiration with serious consequences is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/10,23\">",
"     10,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183703\">",
"    <span class=\"h3\">",
"     Urgent or emergent procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of fasting prior to procedural sedation for urgent or emergent procedures is controversial and disparate recommendations have been proposed by the American Society of Anesthesiologists and the American College of Emergency Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/10,20\">",
"     10,20",
"    </a>",
"    ]. We advise the following approach to reducing aspiration risk for children undergoing sedation for urgent or emergent",
"    <strong>",
"    </strong>",
"    procedures outside of the operating room:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carefully consider the risks and benefits of performing the procedure in patients who do not meet American Society of Anesthesiologists (ASA) fasting guidelines. Although there is no proof that longer fasting times reduce aspiration risk, it is reasonable to wait if the child has not fasted and the procedure is not a true emergency [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6183696\">",
"       'Elective procedures'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Waiting until fasting guidelines are met is appropriate when an increased risk for aspiration exists, such as with the following circumstances [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/20\">",
"       20",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Possibility of a difficult airway (see",
"      <a class=\"local\" href=\"#H11046848\">",
"       'Airway assessment'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Conditions predisposing to esophageal reflux (ie, elevated intracranial pressure, gastritis, bowel obstruction, or ileus)",
"     </li>",
"     <li>",
"      Young infants (eg, &lt;6 months)",
"     </li>",
"     <li>",
"      Severe systemic disease with functional limitation (ASA class &ge;3) (see",
"      <a class=\"local\" href=\"#H1560699\">",
"       'Risk classification'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Other clinical considerations that the clinician may judge to increase aspiration risk (eg, altered mental status).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decrease the targeted depth of sedation. Limited evidence in children has associated the risk of adverse effects with depth of sedation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/12\">",
"       12",
"      </a>",
"      ]. Lighter sedation may permit the patient to maintain protective airway reflexes, which reduces risk.",
"     </li>",
"     <li>",
"      When fasting guidelines are not met, deep sedation should be avoided, if possible. In patients with recent significant oral intake (eg, large meal within two hours of sedation) for whom deep sedation is necessary and procedural delay is not possible, many experts would suggest rapid sequence intubation prior to sedation, although evidence is lacking as to whether this approach reduces aspiration risk. Consultation with an anesthesiologist or other sedation expert is advised.",
"     </li>",
"     <li>",
"      Administration of pre-procedural antacids or motility agents have not been shown to reduce aspiration risk and are not indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases in which the procedure cannot be delayed and the risk of adverse events is anticipated to be significant, general anesthesia in the operating room, if available, may be preferred, although this approach has not been proven to reduce the risk of aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/22,27\">",
"     22,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between fasting state and adverse events, including pulmonary aspiration, for children undergoing procedural sedation and analgesia in the emergency department has been evaluated in the following observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective case series of 905 children receiving procedural sedation consisting primarily of sedation with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      , ketamine and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      , midazolam and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/38/2662?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"       pentobarbital",
"      </a>",
"      and performed in a pediatric emergency department, the 509 children who did not meet ASA fasting guidelines for elective procedures did",
"      <strong>",
"       not",
"      </strong>",
"      have significantly more adverse events, including vomiting, than patients who did (8 versus 7 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/12\">",
"       12",
"      </a>",
"      ]. No episodes of pulmonary aspiration occurred and, based upon this finding, the authors provided an estimate of four episodes of pulmonary aspiration per 1000 pediatric sedations that do not adhere to ASA guidelines. Adverse events",
"      <strong>",
"       were",
"      </strong>",
"      associated with deeper levels of sedation. Median fasting for all patients was seven hours for solids and six hours for liquids.",
"     </li>",
"     <li>",
"      In a series of 2085 children receiving parenteral sedation primarily with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      , ketamine and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      , or midazolam and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      in a pediatric emergency department, there was no difference in the incidence of adverse events (oxygen desaturation, vomiting, apnea, laryngospasm) between those who met fasting guidelines and those who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/28\">",
"       28",
"      </a>",
"      ]. No episodes of pulmonary aspiration occurred. Approximately 150 children had fasting times that were two hours or less and 400 children had fasting times between two and four hours.",
"     </li>",
"     <li>",
"      In a prospective observational study of 218 children who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      mixed with oxygen for procedural sedation in a pediatric emergency department, 71 percent of patients did not meet fasting guidelines for solids (median duration four hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/29\">",
"       29",
"      </a>",
"      ]. There were no serious adverse events, including oxygen desaturation or pulmonary aspiration. There was no association between duration of fasting and emesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that aspiration during procedural sedation in children remains a rare event in the pediatric emergency department setting and that fasting status does not appear to be associated with important adverse events. However, most patients in all of these studies had some degree of fasting and the estimate regarding the potential for pulmonary aspiration (4 in 1000 patients) is still higher than the incidence of aspiration reported in adults who meet ASA fasting guidelines and undergo general anesthesia in the operating room (1 in 7000) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/14\">",
"     14",
"    </a>",
"    ]. Furthermore, these sedations were performed by practitioners with a high level of pediatric airway and resuscitation expertise in settings that encouraged careful assessment and close monitoring. Thus, more data would be helpful in providing clear guidance.",
"   </p>",
"   <p>",
"    If their fasting guidelines cannot be met, the ASA approach is to recommend that the clinician consider delaying the procedure, reducing the level of sedation, or protecting the airway with endotracheal intubation. Implementing these guidelines for patients with emergency conditions presents several issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many children requiring emergent sedation do",
"      <strong>",
"       not",
"      </strong>",
"      meet the ASA fasting criteria.",
"     </li>",
"     <li>",
"      Emergent procedures often cannot be delayed.",
"     </li>",
"     <li>",
"      Endotracheal intubation may not protect the patient from aspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/20,21,23,27,30,31\">",
"       20,21,23,27,30,31",
"      </a>",
"      ]. Aspiration can occur despite the presence of an endotracheal tube, while the airway manipulation involved in performing intubation appears to increase the risk of aspiration as well as other risks associated with rapid sequence intubation in otherwise healthy children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative approach is provided by the American College of Emergency Physicians (ACEP) policy statement on procedural sedation as follows: \"Recent food intake is not a contraindication for administering procedural sedation and analgesia, but should be considered in choosing the timing and target of sedation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/32\">",
"     32",
"    </a>",
"    ]. The expert panel further suggests that the provider modify the depth and length of procedural sedation based upon the timing and nature of the last oral intake, the urgency of the procedure, and the risk for aspiration (",
"    <a class=\"graphic graphic_figure graphicRef52081 \" href=\"UTD.htm?5/2/5159\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United Kingdom, the National Institute for Health and Clinical Excellence (NICE) has provided guidance for sedation in children that promotes an approach to preparation and patient assessment that is similar to the ACEP guidelines regarding decisions about depth and length of procedural sedation for children with the following exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fasting is not needed for:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sedation with 50 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"       nitrous oxide",
"      </a>",
"      (in oxygen) alone",
"     </li>",
"     <li>",
"      Moderate sedation where the child maintains verbal contact",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fasting that corresponds to the American Society for Anesthesiology guideline (two hours for clear liquids; four hours for breast milk; and six hours for formula, non-human milk, and solids) is advised for patients undergoing the following types of sedation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Moderate sedation where the child might not maintain verbal contact",
"     </li>",
"     <li>",
"      Deep sedation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of which fasting guidelines are used in children undergoing urgent or emergent procedures, serious adverse events following pediatric sedation outside the operating room do occur, and clinicians who perform pediatric sedation should use fasting status and urgency of the procedure to decide the timing of sedation relative to last oral intake, the target depth of sedation, and the specific medications used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560699\">",
"    <span class=\"h2\">",
"     Risk classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Anesthesiologists (ASA) classification allows providers to place patients in general categories of health from normal health to near death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/6\">",
"     6",
"    </a>",
"    ]. As part of the pre-sedation evaluation, an ASA Classification should be given to each patient as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I &ndash; A normally healthy patient",
"     </li>",
"     <li>",
"      Class II &ndash; A patient with mild systemic disease (eg, mild asthma, controlled diabetes mellitus)",
"     </li>",
"     <li>",
"      Class III &ndash; A patient with severe systemic disease (eg, moderate-to-severe asthma, poorly controlled diabetes mellitus, pneumonia)",
"     </li>",
"     <li>",
"      Class IV &ndash; A patient with severe systemic disease that is a constant threat to life (eg, severe bronchopulmonary dysplasia, advanced cardiac disease)",
"     </li>",
"     <li>",
"      Class V &ndash; A moribund patient who is not expected to survive without the operation (eg, septic shock, severe trauma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the ASA classification was not specifically designed to rate sedation risk, the ASA classification does appear to correlate with appropriateness for sedation. Children with ASA classes I and II are generally reasonable candidates for mild, moderate, and deep sedation by personnel other than anesthesiologists, outside of the operating room. Those patients with ASA classes III, IV, and V, special needs, or airway abnormalities warrant consultation with a pediatric anesthesiologist or clinician with similar pediatric sedation expertise (eg, emergency physician, pediatric intensivist) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/6\">",
"     6",
"    </a>",
"    ]. The balance of risks and benefits must be weighed for each individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11046848\">",
"    <span class=\"h2\">",
"     Airway assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence specific for children regarding identification and management of difficult airways is limited. Nevertheless, a reasonable, systematic approach for children can be developed from experience with adult patients in the operating room and emergency department using the mnemonic LEMON&copy; (",
"    <a class=\"graphic graphic_table graphicRef64336 \" href=\"UTD.htm?0/46/747\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link&amp;anchor=H12#H12\">",
"     \"The difficult pediatric airway\", section on 'Identification of the difficult pediatric airway'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       L",
"      </strong>",
"      : Look externally for indicators of a difficult airway (ie, a misshapen head, facial abnormalities, or neck masses).",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      : Evaluate mouth opening, thyromental distance, and the distance between the mandible and the thyroid cartilage (this correlates with the distance between the base of the tongue and the larynx) (",
"      <a class=\"graphic graphic_picture graphicRef60507 \" href=\"UTD.htm?37/23/38256\">",
"       picture 1",
"      </a>",
"      ). Adequate mouth opening and thyromental distance should be the width of three of the patient's fingers. The distance between the mandible and thyroid cartilage should be the width of two fingers.",
"     </li>",
"     <li>",
"      <strong>",
"       M",
"      </strong>",
"      : Mallampati score (",
"      <a class=\"graphic graphic_figure graphicRef75229 \" href=\"UTD.htm?2/36/2626\">",
"       figure 2",
"      </a>",
"      ): Assigning a Mallampati score may be difficult in young children. For the obtunded, supine patient, a crude assessment can be made using a tongue blade [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       O",
"      </strong>",
"      : Obstruction: Signs of airway obstruction (ie, stridor, a muffled voice, or difficulty handling secretions) always indicate that airway management may be difficult. Upper airway obstruction can interfere with bag mask ventilation, as well as with laryngoscopy and intubation.",
"     </li>",
"     <li>",
"      <strong>",
"       N",
"      </strong>",
"      : Neck mobility: Conditions that limit neck mobility (ie, congenital anomalies or cervical spine immobilization) can usually be identified by observation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1563046\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to performing urgent or elective procedural sedation, the clinician should obtain informed assent or consent from the patient, and if indicated, informed consent from the primary caregiver and ensure that the proper personnel, monitoring capability, and equipment are present to perform the procedure in a safe manner. Whenever possible, informed consent should also be obtained prior to sedation for emergent conditions, although in some instances, the patient&rsquo;s condition may not allow delay for informed consent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1563157\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components of the informed consent for procedural sedation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The specific medications that will be administered, potential side effects (eg, vomiting, respiratory depression, laryngospasm, emergence reaction), and the likely duration of sedation",
"     </li>",
"     <li>",
"      Precautions taken to manage adverse effects that might occur, including frequent assessment, continuous monitoring, personnel dedicated to performing the sedation, and immediate availability of resuscitation equipment, and if applicable, reversal agents",
"     </li>",
"     <li>",
"      Alternative agents and why they are not being used",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Caregivers who choose to remain with the child during sedation should be informed that their child&rsquo;s appearance during sedation may be upsetting (eg, blank stare or nystagmus with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    ) and that the child may vocalize or have other nonspecific behaviors that indicate discomfort despite effective procedural sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560713\">",
"    <span class=\"h2\">",
"     Personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians who administer sedation must understand the pharmacology of the drugs they use and be comfortable choosing a procedural sedation plan for the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/33\">",
"     33",
"    </a>",
"    ]. Because depression of consciousness is a continuum (except for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    ) and responses to medications vary, clinicians must be able to deal with complications in patients whose level of sedation becomes deeper than intended or who experience an adverse reaction to medication. Competence in emergency airway management is mandatory if deep sedation is intended or possible and is strongly advised for lighter levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of sedation requires at least two individuals, typically an advanced practice clinician (eg, physician, physician&rsquo;s assistant, advanced practice registered nurse, nurse anesthetist) and an assistant. In addition to the assistant, it is preferable to have two advanced practice clinicians present (one to administer the sedation, while the other performs the procedure) whenever possible for patients undergoing moderate to deep sedation. At least one person present should have training in pediatric resuscitation and be skilled in airway management and cardiopulmonary resuscitation. In any case, there should be a competent individual available to monitor continuously and document vital signs, level of consciousness, drug administration, and any complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560720\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The temperature, heart rate, respirations, and blood pressure should be measured and recorded prior to initiating procedural sedation. Monitoring equipment appropriate to the degree of sedation should be ready for use as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29432/abstract/6\">",
"     6",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1683246#H1683246\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Monitoring'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild sedation &ndash; Pulse oximetry and heart rate",
"     </li>",
"     <li>",
"      Moderate or deep sedation &ndash; Pulse oximetry, capnography or continuous visual monitoring of breathing (face, mouth, and chest wall movement), heart rate, respirations, and blood pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560727\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving deep sedation should have an intravenous catheter in place for administration of multiple doses of medication or for resuscitation, if needed. Although desirable, intravenous access is not mandatory for lighter levels of sedation or when sedative agents are given by oral, nasal, rectal, or intramuscular routes. If the procedure is performed without an intravenous catheter, equipment and personnel capable of establishing vascular access should be immediately available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560734\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the monitoring devices mentioned above (pulse oximeter, electrocardiograph monitor, and ETCO2 monitoring when available), equipment of appropriate size must be immediately accessible for management of the airway and resuscitation. This equipment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygen",
"     </li>",
"     <li>",
"      Bag-mask system for positive pressure ventilation",
"     </li>",
"     <li>",
"      Laryngoscope with appropriately sized blades and endotracheal tubes and appropriate rescue airway devices (eg, laryngeal mask airway) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37593?source=see_link\">",
"       \"Emergency rescue devices for difficult pediatric airway management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Suction catheters and apparatus",
"     </li>",
"     <li>",
"      Emergency cart with appropriate medications",
"     </li>",
"     <li>",
"      Defibrillator",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergency equipment and medications must be checked on a routine basis to ensure their availability, if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1562088\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to provide safe and effective procedural sedation is essential in many healthcare settings. To accomplish this, the following factors should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We and the American Society of Anesthesiology suggest that children, undergoing sedation for scheduled",
"      <strong>",
"       elective",
"      </strong>",
"      procedures outside of the operating room, fast two hours for clear liquids; four hours for breast milk; and six hours for formula, non-human milk, and solids prior to sedation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The strength of this recommendation recognizes that guidelines for fasting and sedation outside of the operating room are based upon expert consensus. Aspiration is a rare, but potentially life-threatening event after sedation. Thus, superiority of a particular approach to fasting is difficult to demonstrate. (See",
"      <a class=\"local\" href=\"#H11047750\">",
"       'Fasting and aspiration risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who may require urgent or emergent procedural sedation should receive nothing by mouth throughout their initial evaluation. Fasting status and the urgency of the procedure should be used to determine the timing of sedation, target depth of sedation, and the specific agents used, but recent oral intake is not a contraindication for emergent procedural sedation. (See",
"      <a class=\"local\" href=\"#H11047750\">",
"       'Fasting and aspiration risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pre-sedation evaluation should identify children who may experience serious adverse events with sedation in accordance with the American Society of Anesthesiologists (ASA) classification system and those with a potential difficult airway. Healthy patients or those with mild systemic disease (ASA class I or II) and no evidence of a difficult airway are suitable candidates for procedural sedation outside of the operating room. Patients with severe or poorly controlled systemic disease (ASA class III, IV, or V) or a strong potential for a difficult airway warrant the involvement of a pediatric anesthesiologist or clinician with similar pediatric sedation expertise. (See",
"      <a class=\"local\" href=\"#H1560699\">",
"       'Risk classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11046848\">",
"       'Airway assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Personnel should have the ability to manage possible complications. Specifically, they must be able to recognize the patient who is compromised and have the necessary skills to intervene. These skills include, at a minimum, the ability to maintain the child's airway with repositioning and to provide bag-mask ventilation. (See",
"      <a class=\"local\" href=\"#H1560713\">",
"       'Personnel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of sedation requires at least two individuals, typically an advanced practice clinician (eg, physician, physician&rsquo;s assistant, advanced nurse practitioner, nurse anesthetist) and an assistant. In addition to the assistant, it is preferable to have two advanced practice clinicians present (one to administer the sedation, while the other performs the procedure) whenever possible for patients undergoing moderate to deep sedation. At least one person present should be trained in pediatric resuscitation and be skilled in airway management and cardiopulmonary resuscitation. (See",
"      <a class=\"local\" href=\"#H1560713\">",
"       'Personnel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving deep sedation should have an intravenous catheter in place for administration of multiple doses of medication or for resuscitation, if needed. Although desirable, intravenous access is not mandatory for lighter levels of sedation or when sedative agents are given by oral, nasal, rectal, or intramuscular routes. If the procedure is performed without an intravenous catheter, equipment and personnel capable of establishing vascular access should be immediately available. In addition to the monitoring devices mentioned above (pulse oximeter, electrocardiograph monitor, and ETCO2 monitoring when available), resuscitation equipment and medications should be immediately accessible. (See",
"      <a class=\"local\" href=\"#H1560727\">",
"       'Vascular access'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1560734\">",
"       'Equipment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/1\">",
"      Bhatt M, Kennedy RM, Osmond MH, et al. Consensus-based recommendations for standardizing terminology and reporting adverse events for emergency department procedural sedation and analgesia in children. Ann Emerg Med 2009; 53:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/2\">",
"      Zempsky WT, Cravero JP, American Academy of Pediatrics Committee on Pediatric Emergency Medicine and Section on Anesthesiology and Pain Medicine. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics 2004; 114:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/3\">",
"      Howard RF. Current status of pain management in children. JAMA 2003; 290:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/4\">",
"      Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet 2006; 367:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/5\">",
"      Cravero JP, Blike GT. Review of pediatric sedation. Anesth Analg 2004; 99:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/6\">",
"      American Academy of Pediatrics, American Academy of Pediatric Dentistry, Cot&eacute; CJ, et al. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics 2006; 118:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/7\">",
"      Sacchetti A, Schafermeyer R, Geradi M, et al. Pediatric analgesia and sedation. Ann Emerg Med 1994; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/8\">",
"      Cot&eacute; CJ. \"Conscious sedation\": time for this oxymoron to go away! J Pediatr 2001; 139:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/9\">",
"      Green SM, Krauss B. The semantics of ketamine. Ann Emerg Med 2000; 36:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/10\">",
"      American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002; 96:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/11\">",
"      Mandt MJ, Roback MG. Assessment and monitoring of pediatric procedural sedation. Clin Ped Emerg Med 2007; 8:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/12\">",
"      Agrawal D, Manzi SF, Gupta R, Krauss B. Preprocedural fasting state and adverse events in children undergoing procedural sedation and analgesia in a pediatric emergency department. Ann Emerg Med 2003; 42:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/13\">",
"      Cheung KW, Watson ML, Field S, Campbell SG. Aspiration pneumonitis requiring intubation after procedural sedation and analgesia: a case report. Ann Emerg Med 2007; 49:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/14\">",
"      Sakai T, Planinsic RM, Quinlan JJ, et al. The incidence and outcome of perioperative pulmonary aspiration in a university hospital: a 4-year retrospective analysis. Anesth Analg 2006; 103:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/15\">",
"      Warner MA, Warner ME, Warner DO, et al. Perioperative pulmonary aspiration in infants and children. Anesthesiology 1999; 90:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/16\">",
"      Green SM, Krauss B. Pulmonary aspiration risk during emergency department procedural sedation--an examination of the role of fasting and sedation depth. Acad Emerg Med 2002; 9:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/17\">",
"      Brady M, Kinn S, Stuart P. Preoperative fasting for adults to prevent perioperative complications. Cochrane Database Syst Rev 2003; :CD004423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/18\">",
"      Miner JR, Burton JH. Clinical practice advisory: Emergency department procedural sedation with propofol. Ann Emerg Med 2007; 50:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/19\">",
"      Sandhar BK, Goresky GV, Maltby JR, Shaffer EA. Effect of oral liquids and ranitidine on gastric fluid volume and pH in children undergoing outpatient surgery. Anesthesiology 1989; 71:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/20\">",
"      Green SM, Roback MG, Miner JR, et al. Fasting and emergency department procedural sedation and analgesia: a consensus-based clinical practice advisory. Ann Emerg Med 2007; 49:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/21\">",
"      S&oslash;reide E, Eriksson LI, Hirlekar G, et al. Pre-operative fasting guidelines: an update. Acta Anaesthesiol Scand 2005; 49:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/22\">",
"      Brady M, Kinn S, O'Rourke K, et al. Preoperative fasting for preventing perioperative complications in children. Cochrane Database Syst Rev 2005; :CD005285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/23\">",
"      Splinter WM, Stewart JA, Muir JG. Large volumes of apple juice preoperatively do not affect gastric pH and volume in children. Can J Anaesth 1990; 37:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/24\">",
"      Green SM. Fasting is a consideration--not a necessity--for emergency department procedural sedation and analgesia. Ann Emerg Med 2003; 42:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/25\">",
"      Ljungqvist O, S&oslash;reide E. Preoperative fasting. Br J Surg 2003; 90:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/26\">",
"      Bassett KE, Anderson JL, Pribble CG, Guenther E. Propofol for procedural sedation in children in the emergency department. Ann Emerg Med 2003; 42:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/27\">",
"      Engelhardt T, Webster NR. Pulmonary aspiration of gastric contents in anaesthesia. Br J Anaesth 1999; 83:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/28\">",
"      Roback MG, Bajaj L, Wathen JE, Bothner J. Preprocedural fasting and adverse events in procedural sedation and analgesia in a pediatric emergency department: are they related? Ann Emerg Med 2004; 44:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/29\">",
"      Babl FE, Puspitadewi A, Barnett P, et al. Preprocedural fasting state and adverse events in children receiving nitrous oxide for procedural sedation and analgesia. Pediatr Emerg Care 2005; 21:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/30\">",
"      Olsson GL, Hallen B, Hambraeus-Jonzon K. Aspiration during anaesthesia: a computer-aided study of 185,358 anaesthetics. Acta Anaesthesiol Scand 1986; 30:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/31\">",
"      Blitt CD, Gutman HL, Cohen DD, et al. \"Silent\" regurgitation and aspiration during general anesthesia. Anesth Analg 1970; 49:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/32\">",
"      Godwin SA, Caro DA, Wolf SJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med 2005; 45:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/33\">",
"      Sury M, Bullock I, Rabar S, et al. Sedation for diagnostic and therapeutic procedures in children and young people: summary of NICE guidance. BMJ 2010; 341:c6819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29432/abstract/34\">",
"      Cot&eacute; CJ, Notterman DA, Karl HW, et al. Adverse sedation events in pediatrics: a critical incident analysis of contributing factors. Pediatrics 2000; 105:805.",
"     </a>",
"    </li>",
"    <li>",
"     Murphy, MF, Walls, RM. Identification of the difficult and failed airway. In: Manual of emergency airway management, 2nd, Walls, RM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.74.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16900 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29432=[""].join("\n");
var outline_f28_47_29432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1562088\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1560650\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1560678\">",
"      GOALS OF SEDATION AND ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1560685\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1560692\">",
"      PRE-SEDATION EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6183724\">",
"      Focused medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11047750\">",
"      Fasting and aspiration risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6183696\">",
"      - Elective procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6183703\">",
"      - Urgent or emergent procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560699\">",
"      Risk classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11046848\">",
"      Airway assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1563046\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1563157\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560713\">",
"      Personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560720\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560727\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560734\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1562088\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/16900\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16900|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/2/5159\" title=\"figure 1\">",
"      Assess aspiration risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/36/2626\" title=\"figure 2\">",
"      Modified Mallampati airway classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16900|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/23/38256\" title=\"picture 1\">",
"      3 3 2 rule for identifying a difficult airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16900|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/46/747\" title=\"table 1\">",
"      LEMON mnemonic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37593?source=related_link\">",
"      Emergency rescue devices for difficult pediatric airway management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31194?source=related_link\">",
"      Pharmacologic agents for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_47_29433="Infection in the solid organ transplant recipient";
var content_f28_47_29433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infection in the solid organ transplant recipient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/47/29433/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29433/contributors\">",
"     Jay A Fishman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/47/29433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29433/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/47/29433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/47/29433/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/47/29433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid organ transplantation has increased worldwide since the first successful human kidney transplant was performed in 1954. As immunosuppressive agents and graft survival have improved, infection and malignancy have become the main barriers to disease-free survival after organ transplantation. As a result of the growing population of immunosuppressed patients with prolonged survival, an increased incidence and spectrum of opportunistic infections is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Guidelines for the diagnosis and treatment of infection in transplant recipients have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risks of infection and an overview of specific infections in the solid organ transplant recipient will be reviewed here. The pretransplant evaluation for solid organ and hematopoietic cell transplant (HCT) recipients, prophylaxis of infections in solid organ transplant and HCT recipients, and an overview of infections following HCT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"     \"Evaluation for infection before hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When infection occurs, early and specific diagnosis and rapid and aggressive treatment are essential to good clinical outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential etiologies of infection in these patients are diverse, including common, community-acquired bacterial and viral diseases and uncommon opportunistic infections of clinical significance only in immunocompromised hosts [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. Pulmonary processes can progress rapidly and may constitute medical emergencies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/1\">",
"       1",
"      </a>",
"      ]. These include infections due to Pneumocystis jirovecii (formerly P. carinii), Nocardia asteroides, Aspergillus spp, Cryptococcus neoformans, cytomegalovirus (CMV), varicella zoster virus (VZV), influenza, respiratory syncytial virus (RSV), Rhodococcus equi, and Legionella spp.",
"     </li>",
"     <li>",
"      Inflammatory responses associated with microbial invasion are impaired by immunosuppressive therapy, which results in diminished symptoms and muted clinical and radiologic findings. As a result, infections are often advanced (ie, disseminated) at the time of clinical presentation.",
"     </li>",
"     <li>",
"      Serologic testing is not generally useful for the diagnosis of acute infection in the immunocompromised host since seroconversion is often delayed. Serologic assays may be used to identify latent infections and distant exposures as a basis for prophylaxis. Microbiologic cultures are supplemented by antigen-based tests (eg, enzyme linked immunosorbent assays [ELISA]) or nucleic acid-based molecular assays (eg, polymerase chain reaction [PCR]) for diagnosis in this population.",
"     </li>",
"     <li>",
"      Altered anatomy following transplant surgery may change the physical signs of infection. Diagnosis often requires anatomic data from imaging such as computed tomographic (CT) scans or magnetic resonance imaging (MRI).",
"     </li>",
"     <li>",
"      Tissue biopsies with histopathology and microbiology are often needed to make a specific microbiologic diagnosis in transplant recipients. Such clinical samples must be obtained early in the clinical course to enhance the chance for successful therapy, to minimize side effects of therapy, and before the patient's illness progresses to a point where such procedures can no longer be performed.",
"     </li>",
"     <li>",
"      The choice of antimicrobial regimens is often more complex than in other patients due to the urgency of therapy and the frequency of drug toxicities and drug interactions.",
"     </li>",
"     <li>",
"      Antimicrobial resistance is increased in immunocompromised hosts and should be considered in the choice of antimicrobial regimens.",
"     </li>",
"     <li>",
"      Surgical intervention is often necessary to cure localized infections (ie, debridement); antimicrobial agents alone are frequently inadequate.",
"     </li>",
"     <li>",
"      Drug levels provide only crude means of monitoring immunosuppressive regimens and patients are often more or less immunosuppressed than anticipated. Side effects of these regimens are also common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all of these reasons, the central focus must be on disease prevention, including drug therapy and vaccination. This requires stratification of the risk for various infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK OF INFECTION FOLLOWING TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of infection in the organ transplant patient is determined by a semi-quantitative relationship between two factors: the epidemiologic exposures of the individual and the \"net state of immunosuppression\" which is a measure of all of the factors that contribute to the individual's susceptibility (or resistance) to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/1-3,5\">",
"     1-3,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiologic exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;To adequately assess epidemiologic exposures, the clinician must take a detailed history of potential encounters with a variety of pathogens, even if the exposure was relatively remote. Latent pathogens are often activated in the setting of immune suppression. The epidemiologic exposures of importance to an individual will vary based upon the nature of the immune deficits. Most transplant patients have multiple deficits. Thus, bacterial and fungal pathogens are more important in the setting of neutropenia while viral (eg, cytomegalovirus [CMV]) and intracellular (eg, tuberculosis [TB]) infections are more common with T cell immune deficits. Strongyloides stercoralis may reactivate many years following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Community-acquired pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transplant recipient can have contact with a number of potential pathogens within the community. These organisms include common respiratory viruses (influenza, parainfluenza, respiratory syncytial [RSV] virus, adenovirus, and human metapneumovirus). In addition, common bacterial pathogens may include: Streptococcus pneumoniae, Mycoplasma, Legionella, Listeria monocytogenes, and Salmonella. Vaccinations for pneumococcus and influenza virus are useful but may have reduced efficacy in immunocompromised individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the appropriate geographic regions, endemic fungi (Histoplasma capsulatum, Coccidioides spp, Blastomyces dermatitidis, Cryptococcus gattii), and common environmental pathogens (eg, Cryptococcus neoformans, Aspergillus spp, Cryptosporidia spp) will be observed. Thus, while specific infectious exposures within the community will vary based upon such factors as geography and socioeconomic status, the general dictum that \"common things occur commonly\" applies to transplant recipients. However, the severity and duration of infection, and the frequency of multiple simultaneous processes are features that differentiate the transplant recipient from the normal host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Reactivation of infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivated infection may be derived from the organ donor or the recipient. Common viral infections that frequently reactivate following transplantation include herpes simplex virus (HSV), CMV, varicella zoster virus (VZV, shingles), hepatitis B (HBV), and hepatitis C (HCV), papillomavirus, and BK polyomavirus. Some exposures may have occurred many years before transplantation including geographically restricted systemic mycoses (eg, histoplasmosis, coccidioidomycosis, blastomycosis), Mycobacterium tuberculosis, Strongyloides stercoralis, Leishmania spp, or Trypanosoma cruzi [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important goal of the pretransplant evaluation is to identify such latent infections so as to develop a preventive strategy for each.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nosocomial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant recipients are vulnerable to nosocomial infections, especially in the early posttransplant (ie, post-surgical) period in patients with prolonged hospitalizations or who require mechanical ventilation. Pathogens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Legionella spp and other gram-negative bacilli such as Pseudomonas aeruginosa",
"     </li>",
"     <li>",
"      Gram-positive organisms, particularly antimicrobial resistant species such as vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA)",
"     </li>",
"     <li>",
"      Fungi such as Aspergillus spp and non-albicans or azole-resistant Candida species (",
"      <a class=\"graphic graphic_table graphicRef80777 \" href=\"UTD.htm?24/25/24987\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Clostridium difficile colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the air, food, equipment, or potable water supply either in the hospital or the home are contaminated with pathogens such as Aspergillus spp, Legionella spp, or gram-negative bacilli, clusters of infection can be observed in time",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Donor-derived infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections that are derived from donor organ tissues and activated in the recipient are among the most important exposures in transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Some of these infections are latent, while others are the result of bad timing (unappreciated active infection in the donor at the time of transplantation). The efficiency of the transmission of infectious diseases is likely to be greatest in immunosuppressed transplant recipients.&nbsp;As a result, these individuals act as sentinels for transmissible diseases. In immunosuppressed hosts, classic signs of infections (eg, leukocytosis, erythema) may be replaced by non-specific signs (eg, altered mental status, elevation of blood liver function tests, wound dehiscence, unexplained hypotension). As an example, in immunosuppressed hosts, the transmission of bloodborne or organ-derived infection due to West Nile Virus more often manifests as neurologic disease with poor clinical outcomes than in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/14\">",
"     14",
"    </a>",
"    ]. Clusters of infection associated with organ transplantation have also included tuberculosis, Candida and Aspergillus (and other fungal) species, herpes simplex virus,human herpes virus 8, lymphocytic choriomeningitis virus (LCMV), rabies virus, Chagas disease, Balamuthia mandrillaris [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], HIV, and hepatitis C virus. &nbsp;",
"   </p>",
"   <p>",
"    Organ donors are screened to avoid transmission of certain infections to transplant recipients (",
"    <a class=\"graphic graphic_table graphicRef55861 \" href=\"UTD.htm?33/9/33948\">",
"     table 2",
"    </a>",
"    ). Nonetheless, transmission of infection from donor to recipient may still occur (",
"    <a class=\"graphic graphic_table graphicRef80504 \" href=\"UTD.htm?2/19/2364\">",
"     table 3",
"    </a>",
"    ). The data supporting transmission of the individual infections are discussed separately in the appropriate topic reviews for each infection.",
"   </p>",
"   <p>",
"    Several types of infection merit special attention: bloodstream infection, inapparent infections that are accelerated by immunosuppression, and a number of specific infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bloodstream infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some donors may have active infection at the time of procurement. Certain bloodstream infections (eg, staphylococci, pneumococcus, Candida, Salmonella, E. coli) may \"stick\" to anastomotic sites (vascular, urinary, biliary, tracheal), and produce fever, bacteremia, or mycotic aneurysms. Proof of adequate therapy for such infections must be established prior to accepting organs for transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inapparent infections accelerated by immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other infections may be inapparent or unusual (eg, West Nile virus, leishmaniasis, rabies, lymphocytic choriomeningitis virus, Chagas disease, HIV, herpes simplex virus) and may cause clinical syndromes that are accelerated by immune suppression.",
"   </p>",
"   <p>",
"    As an example, lymphocytic choriomeningitis virus infection (LCMV) occurred in the recipients of solid organ transplants from three different donors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In the investigation of the first two clusters, LCMV was identified in tissues in all organ transplant recipients from both investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/17\">",
"     17",
"    </a>",
"    ]. The isolates from each investigation were identical to each other but distinct between the two outbreaks. In contrast, the common donors had no clinical or laboratory evidence of infection, although the donor from the 2005 cluster had a history of exposure to a pet hamster. Seven of eight transplant recipients died; one survivor was treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and decreasing doses of immunosuppressants. An epidemiologic investigation, using phylogenetic analysis of virus sequences, eventually traced the origin of these infections to an animal distribution center in Ohio [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three patients in Australia who received a kidney or liver from a single donor died of a febrile illness with associated encephalopathy four to six weeks after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/20\">",
"     20",
"    </a>",
"    ]. High-throughput RNA sequencing from the allografts of two of the patients revealed an arenavirus that is related to LCMV. These results were confirmed by immunohistochemical analysis of allograft tissue as well as IgM and IgG antiviral antibodies from the serum of the donor. In addition, PCR revealed the presence of the virus in the kidneys, liver, blood, and cerebrospinal fluid of the recipients. The donor had just returned home from a three-month visit to rural areas of the former Yugoslavia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     CMV and EBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are associated with particular syndromes and morbidity in the immunocompromised population. The greatest risk for invasive infection is seen in recipients who are seronegative (immunologically naive) and receive infected grafts from seropositive donors (latent viral infection). This risk constitutes the rationale for anti-CMV prophylaxis in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link\">",
"     \"Infectious complications in liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Tuberculosis and histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late, latent infections including tuberculosis and histoplasmosis may activate many years after transplantation. Early emergence of tuberculosis in recipients has also been described after receiving organs from a donor with undiagnosed active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mycobacterial infection may be difficult to treat after transplantation because of interactions between the antimicrobial agents used to treat infection (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ) and immunosuppressive drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation and management of tuberculosis in lung transplant recipients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     HIV, HTLV, and hepatitis viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2007, four recipients of organs from a single donor, who had died from trauma, were infected with both HIV and hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/23\">",
"     23",
"    </a>",
"    ]. The donor had presumably been infected during the weeks prior to death since the antibody tests for these viruses were negative during the pretransplant donor screening. Other cases of donor-derived hepatitis C infections, as well as hepatitis B infections, have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of tissue donors having viremia due to hepatitis B, hepatitis C, HIV, and human T lymphotropic virus (HTLV) was evaluated in 11,391 tissue donors to five tissue banks in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/26\">",
"     26",
"    </a>",
"    ]. The estimated probability of viremia at the time of donation that would be undetected by screening with current serologic methods (because of the window period for infection) was 1 in 34,000 for hepatitis B, 1 in 42,000 for hepatitis C, 1 in 55,000 for HIV, and 1 in 128,000 for HTLV. The use of nucleic acid amplification testing, which shortens the window period, was estimated to reduce the probabilities of viremia to 1 in 100,000 for hepatitis B, 1 in 421,000 for hepatitis C, and 1 in 173,000 for HIV. However, no available assays can completely exclude the risk of infectious transmissions, especially in the limited time available for decreased donor screening prior to transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Net state of immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The net state of immunosuppression is a complex function determined by the interaction of several factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type, dose, duration, and temporal sequence of immunosuppressive therapies (",
"      <a class=\"graphic graphic_table graphicRef53524 \" href=\"UTD.htm?0/19/316\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Underlying diseases or comorbid conditions",
"     </li>",
"     <li>",
"      Presence of devitalized tissues or fluid collections in the transplanted organ",
"     </li>",
"     <li>",
"      Invasive devices such as vascular access or urinary catheters, surgical drains, and ventricular assist devices",
"     </li>",
"     <li>",
"      Other host factors affecting immune function including neutropenia, hypogammaglobulinemia, and metabolic problems (eg, protein-calorie malnutrition, uremia, diabetes)",
"     </li>",
"     <li>",
"      Concomitant infection with immunomodulating viruses including, CMV, Epstein-Barr virus (EBV), human herpesvirus (HHV)-6 and -7, HBV, HCV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sum of any congenital, acquired, metabolic, operative, and transplant-related factors is the patient's \"net state of immune suppression\". More than one factor is usually present in each host. The identification and correction of any modifiable risk factor is essential for the prevention and treatment of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TIMING OF INFECTION POSTTRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive regimens vary between centers, with the organ transplanted, and the patient population. As an example, \"induction\" with polyclonal or monoclonal anti-T-lymphocyte antisera may be used for renal transplantation from deceased donors but not in living donor transplant recipients or in liver transplant recipients with hepatitis C infection. At some centers, patients may receive little or no glucocorticoid therapy but are treated with combinations of multiple other potent immunosuppressants. Alterations in the type or intensity of immune suppression will alter the risk of infection (",
"    <a class=\"graphic graphic_table graphicRef53524 \" href=\"UTD.htm?0/19/316\">",
"     table 4",
"    </a>",
"    ) and the list of potential pathogens (",
"    <a class=\"graphic graphic_table graphicRef80504 \" href=\"UTD.htm?2/19/2364\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is useful to divide the posttransplant course into three time periods related to the risks of infection by specific pathogens: the early period posttransplant (first month); an intermediate period (one to six months); and more than six months (",
"    <a class=\"graphic graphic_figure graphicRef58770 \" href=\"UTD.htm?21/33/22035\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. This timetable is useful in three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In developing a differential diagnosis for the individual transplant recipient with clinical signs of infection",
"     </li>",
"     <li>",
"      As a clue to the presence of excessive environmental hazards (nosocomial, community or individual)",
"     </li>",
"     <li>",
"      As a guide to the design of preventive antimicrobial strategies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     First month after transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first month posttransplant, there are two major causes of infection in all forms of solid organ transplantation: infection derived from either the donor or recipient and infectious complications of the transplant surgery and hospitalization. The major effects of exogenous immunosuppression are not yet evident. Exceptions include those patients who receive immunosuppression prior to transplantation (eg, for autoimmune hepatitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Donor-derived infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for infections acquired with the allograft have been discussed above (",
"    <a class=\"graphic graphic_table graphicRef80504 \" href=\"UTD.htm?2/19/2364\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/13,34\">",
"     13,34",
"    </a>",
"    ]. Transmission of donor-derived bacteria and fungi has increased with the emergence of antimicrobial resistance such that vancomycin-resistant enterococci, methicillin-resistant staphylococci, and fluconazole-resistant Candida species may be transmitted from donor to recipient. Graft-associated viral infections (LCMV, West Nile virus, rabies, HIV) and parasitic infections (toxoplasmosis, Chagas disease, Balamuthia mandrillaris), are uncommon, but may be amplified in the immunosuppressed host. Endemic infections (eg, histoplasmosis or tuberculosis) should be considered in the differential diagnosis of post-transplant infection or unusual clinical syndromes (eg, encephalitis, hepatitis). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Donor-derived infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection may have been present in the donor or in the recipient prior to transplantation. An important component of the pretransplant evaluation is to recognize and treat such infections, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some common viral infections (eg, hepatitis B virus or hepatitis C virus) may reemerge early after transplantation. Recipient-derived tuberculosis or toxoplasmosis tends to reactivate more than a month after transplantation. Reactivation of Strongyloides may be accompanied by gram-negative bacterial sepsis, meningitis, or pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Infectious complications related to surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid organ transplant recipients develop many of the common postoperative complications, such as aspiration pneumonitis, surgical site (wound) infections, \"line sepsis\", urinary tract infection, or pulmonary embolus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/35\">",
"     35",
"    </a>",
"    ]. Transplant recipients are also at unique risk for superinfection of ischemic or injured graft tissues (eg, anastomotic suture lines), or of fluid collections (eg, hematomas, lymphoceles, pleural effusions, urinomas). These patients are at increased risk for infection associated with indwelling vascular access catheters, urinary catheters, and surgical drains.",
"   </p>",
"   <p>",
"    The organisms responsible for such postoperative complications are often the bacteria and fungi that have colonized the recipient or donor (eg, the lungs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sinuses in cystic fibrosis) prior to transplantation or the local flora of the hospital. Infections acquired prior to transplantation may include relatively resistant nosocomial pathogens (eg, vancomycin-resistant enterococcus) and pathogens such as Aspergillus spp that are resistant to the usual prophylactic agents. Patients receiving antimicrobial agents are at increased risk for C. difficile colitis.",
"   </p>",
"   <p>",
"    Patients at particular risk of nosocomial infection are those requiring prolonged ventilatory support or those with diminished lung function, persistent ascites, stents of the urinary tract or biliary ducts, with intravascular clot or ischemic graft tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/31,36\">",
"     31,36",
"    </a>",
"    ]. Individuals with delayed graft function or who require early reexploration or retransplantation are also at increased risk for infection, notably with fungi or bacteria with antimicrobial resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     One to six months after transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the period one to six months posttransplant, the nature of common infections changes. This is the period when patients are most at risk for the development of opportunistic infections, although residual problems from the perioperative period can persist. There is significant geographic and institutional variation in the occurrence of opportunistic infections during the first six months posttransplantation. This reflects local epidemiology and varying immunosuppressive strategies and also the use of antimicrobial prophylaxis in the post-transplant period. Prevention of the infections observed during this period is the basis of prophylactic antimicrobial strategies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major infections due to opportunistic pathogens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumocystis jirovecii (formerly P. carinii) pneumonia (PCP). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H21#H21\">",
"       \"Fungal infections following lung transplantation\", section on 'Pneumocystis jirovecii'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Latent infections, such as the protozoal diseases including toxoplasmosis, leishmaniasis, and Chagas disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/5,29,30,37-39\">",
"       5,29,30,37-39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The geographic or endemic fungal infections caused by Histoplasma capsulatum, Coccidioides spp, Cryptococcus gattii, and rarely, Blastomyces dermatitidis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"       \"Fungal infections following lung transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viral pathogens, particularly the herpes group viruses but also HBV and HCV. New viruses are recognized as opportunistic pathogens with the use of more sensitive molecular assays (eg, BK polyomavirus, HHV-6, -7, and -8 [Kaposi's sarcoma-associated herpesvirus, KSHV]) (",
"      <a class=\"graphic graphic_table graphicRef55862 \" href=\"UTD.htm?5/55/6012\">",
"       table 5",
"      </a>",
"      ). Respiratory viruses are increasingly important in this population (influenza, parainfluenza, RSV, adenovirus, metapneumovirus).",
"     </li>",
"     <li>",
"      Tuberculosis and, increasingly, non-tuberculous mycobacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"       \"Tuberculosis in solid organ transplant candidates and recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"       \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastrointestinal parasites (Cryptosporidium and Microsporidium) and viruses (CMV, rotavirus) may be associated with diarrhea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     More than six months after transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than six months posttransplant, most patients are receiving stable and reduced levels of immunosuppression. These patients are subject to community-acquired pneumonias due to respiratory viruses, the pneumococcus, Legionella, or other common pathogens.",
"   </p>",
"   <p>",
"    Patients who have less than adequate graft function tend to require higher than usual immunosuppressive therapy. As a result, they represent a subgroup of transplant patients at highest risk for opportunistic infections including PCP, cryptococcosis, and nocardiosis. They are also at risk for severe illness from community-acquired infections due to influenza or Listeria monocytogenes. Prolonged antimicrobial prophylaxis may be indicated for this subgroup of patients, who remain more immunosuppressed. This group of patients may also suffer rare infections in the late transplant period and may have clinical findings that differ from those in immunocompetent hosts. These infections are most often due to molds or Nocardia species or the late effects of viral infections manifest as malignancy: post-transplant lymphoproliferative disorder (PTLD) or squamous cell cancers of the skin or anogenital region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     VIRUSES AS COPATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viruses, particularly CMV, serve as important cofactors to many opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/1,2,27,28,41\">",
"     1,2,27,28,41",
"    </a>",
"    ]. The potential effects of viral infection are diverse and apply not only to CMV but also to HBV, HCV, EBV, and probably other common viruses such as RSV, HHV-6, and adenovirus (",
"    <a class=\"graphic graphic_table graphicRef72973 \" href=\"UTD.htm?16/12/16588\">",
"     table 6",
"    </a>",
"    ). Viruses contribute to a variety of processes post-transplantation (",
"    <a class=\"graphic graphic_table graphicRef55862 \" href=\"UTD.htm?5/55/6012\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/1,28,31,42-44\">",
"     1,28,31,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Direct effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Direct effects\" include clinical syndromes such as fever and neutropenia (CMV), pneumonitis (respiratory viruses), hepatitis (HCV, HBV), gastritis, esophagitis, colitis (CMV), cholangitis (VZV), encephalitis (HSV, JC virus), pancreatitis, myocarditis, and retinitis. Less common syndromes include adrenalitis with adrenal insufficiency or meningoencephalitis due to CMV vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Indirect effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Indirect effects\" are generally immune effects including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune suppression and predisposition to opportunistic infection (eg, Aspergillus after RSV pneumonia, Pneumocystis after CMV infection). Thus, CMV coinfection has been implicated in the accelerated course of HCV infection with cirrhosis and graft loss, and of EBV with increased risk for post-transplant lymphoproliferative disorder (PTLD, usually B-cell lymphoma).",
"     </li>",
"     <li>",
"      Graft rejection that is thought to be mediated by proinflammatory cytokine release",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      upregulation of histocompatibility antigens or adhesion proteins in the setting of CMV reactivation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/42,45,46\">",
"       42,45,46",
"      </a>",
"      ]. Graft rejection may necessitate an increase in the immunosuppressive regimen and an increased risk for opportunistic infection.",
"     </li>",
"     <li>",
"      Oncogenesis: Many viruses predispose to cancer (HCV, EBV) or to cellular proliferation (CMV and accelerated atherogenesis, BK polyomavirus and ureteric smooth muscle cell proliferation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Specific viral pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of viral infections in the transplant recipient has expanded with the discovery of new viruses (",
"    <a class=\"graphic graphic_table graphicRef55862 \" href=\"UTD.htm?5/55/6012\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The BK polyomavirus has been associated with infection of renal allografts with hemorrhagic cystitis, asymptomatic viruria, interstitial nephritis, ureteric obstruction, and rising creatinine values in renal transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"       \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adenovirus may cause a similar hemorrhagic",
"      <span class=\"nowrap\">",
"       nephritis/cystitis",
"      </span>",
"      picture diagnosed by culture or antigen",
"      <span class=\"nowrap\">",
"       detection/immunofluorescence.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link\">",
"       \"Epidemiology and clinical manifestations of adenovirus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HHV-6, -7, and -8 have also been identified in transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link\">",
"       \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14201?source=see_link\">",
"       \"Human herpesvirus 7 infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=see_link\">",
"       \"Disease associations of human herpesvirus 8 infection\"",
"      </a>",
"      .) HHV-6 has been implicated as a cofactor in CMV infection (and vice versa) or may cause leukopenia and fever as part of a viral syndrome. The role of HHV-7 remains to be clarified.",
"     </li>",
"     <li>",
"      EBV, VZV, and HSV are also often activated during this one to six month period. EBV may be associated with the development of B cell non-Hodgkin lymphoma, particularly in seronegative recipients of seropositive organs. However, some cases of T cell, NK cell, and non-EBV related PTLD have been described. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .) Herpes zoster of the skin (shingles) may occur; occasionally, patients present with cholangitis due to VZV. Human papillomavirus (HPV) is associated with anogenital and squamous cell cancers.",
"     </li>",
"     <li>",
"      Parvovirus B19 may also present in this time period with anemia unresponsive to erythropoietin or with myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/51\">",
"       51",
"      </a>",
"      ]. Parvovirus B19 has also been associated with chronic allograft injury in renal transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Respiratory viruses remain important community-acquired pathogens, particularly in the lung transplant recipient [",
"      <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/53\">",
"       53",
"      </a>",
"      ]. Infections with these latter viruses predispose the patient to the development of bacterial infections and graft rejection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pursuit of diagnostic testing and the management of infection in a transplant recipient must be guided by a number of principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These hosts generally have fewer clinical manifestations of infection and few or no findings by conventional radiography. Thus, more sensitive imaging techniques such as computed tomographic (CT) scans and magnetic resonance imaging (MRI) are essential for assessing the presence and nature of infectious and malignant processes.",
"     </li>",
"     <li>",
"      The \"gold standard\" for diagnosis is tissue histology. No radiologic finding is sufficiently diagnostic to obviate the need for tissue. Multiple simultaneous infections are also common. Thus, invasive procedures that provide tissue for culture and histology must be employed early as a routine component of the initial evaluation of transplant recipients with infectious syndromes. Patients failing to respond to appropriate therapy may also need invasive diagnostic procedures.",
"     </li>",
"     <li>",
"      Serologic tests, which indicate past exposure to certain pathogens, are useful in the pretransplant setting to assess risk for relapse of latent disease but are not generally useful after transplantation. Patients, especially those receiving immunosuppressive therapies, do not reliably develop antibodies quickly enough during an active infection to enable a serologic diagnosis. Thus, quantitative tests that directly detect the protein products or nucleic acids of the organisms such as sandwich ELISA, direct immunofluorescence, or molecular assays (hybrid capture, PCR) should be utilized.",
"     </li>",
"     <li>",
"      Transplant recipients are particularly vulnerable to organisms resistant to antimicrobial agents either from the hospital environment or through induction of antibiotic resistance in their flora during therapy (eg, inducible beta-lactamases). Sites at risk for colonization with resistant organisms (eg, ascites, blood clots, drains, lungs) can be sampled so that information is available to guide empiric therapy at times of clinical deterioration.",
"     </li>",
"     <li>",
"      When undrained fluid collections, blood, or devitalized tissues are present, antimicrobial therapy alone is inadequate. Antibiotics, used in lieu of definitive drainage or debridement, merely delay clinical deterioration and promote the acquisition of resistant microorganisms. Early and aggressive surgical debridement of such collections is essential for successful care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many important hurdles remain to be overcome in the diagnosis and treatment of infections to enhance the safety and success of solid organ transplantation. The initiation of a diagnostic evaluation for infection frequently begins when clinical symptoms become manifest. That is often late in the course of the disease in these immunocompromised patients. Further, accurate microbiologic diagnoses are needed to avoid unnecessary toxicities associated with therapy. Thus, invasive diagnostic procedures are often required to make an accurate microbiologic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/47/29433/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More advanced, quantitative laboratory assays utilizing molecular techniques or antigen detection would be welcome. However, currently, such tests often do not offer timely results",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are prohibitively costly for routine use. Rapid, quantitative, cost-effective assays that do not depend upon invasive procedures are needed for the routine monitoring of transplant patients for common infections. The availability of such tests would allow the clinician to individualize prophylactic antimicrobial regimens and minimize drug-associated toxicity.",
"   </p>",
"   <p>",
"    The evolution of pathogens (bacteria, viruses, fungi) with acquired resistance to common antimicrobial agents and the incidence of drug toxicity and allergy have limited the available antimicrobial strategies for transplant recipients. New prophylactic regimens are needed to increase the number of available antiviral and antifungal agents for prophylaxis and therapy and to treat drug-intolerant patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of infection in the organ transplant patient is determined by a semi-quantitative relationship between two factors: the epidemiologic exposures of the individual and the \"net state of immunosuppression\", which is a measure of all of the factors which contribute to the individual's susceptibility (or resistance) to infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk of infection following transplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiologic exposures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Net state of immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is useful to divide the posttransplant course into three time periods related to the risks of infection by specific pathogens: the early period posttransplant (first month); an intermediate period (one to six months); and more than six months (",
"      <a class=\"graphic graphic_figure graphicRef58770 \" href=\"UTD.htm?21/33/22035\">",
"       figure 1",
"      </a>",
"      ). The timing of the presentation of infectious processes will be altered by the deployment of antimicrobial prophylaxis.&nbsp;This may result in the delayed presentation of infection (eg, \"late CMV\").&nbsp; (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Timing of infection posttransplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the first month posttransplant, the major causes of infection in all forms of solid organ transplantation include: infection derived from either the donor or recipient and infectious complications of the transplant surgery and hospitalization. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'First month after transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The period one to six months posttransplant is the period when patients suffer the greatest impact of immunosuppression and are at the greatest risk for the development of opportunistic infections. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'One to six months after transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than six months posttransplant, most patients are receiving stable and reduced levels of immunosuppression. These patients are subject to community-acquired pneumonias due to respiratory viruses, the pneumococcus, Legionella, or other common pathogens. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'More than six months after transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viruses, particularly CMV, serve as important cofactors to many opportunistic infections. The potential effects of viral infection are diverse and apply not only to CMV but also to HBV, HCV, EBV, and probably other common viruses such as RSV, HHV-6, and adenovirus (",
"      <a class=\"graphic graphic_table graphicRef72973 \" href=\"UTD.htm?16/12/16588\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Viruses as copathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pursuit of diagnostic testing and the management of infection in a transplant recipient must be guided by a number of principles:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      These hosts may have nonspecific clinical manifestations of infection and few or no findings by conventional radiography. Thus, more sensitive imaging techniques such as computed tomographic (CT) scans and magnetic resonance imaging (MRI) are necessary.",
"     </li>",
"     <li>",
"      The \"gold standard\" for microbiologic diagnosis includes culture as well as tissue histology. Tests that detect proteins, polysaccharide antigens, or nucleic acids are increasingly important adjunctive diagnostic tests. &nbsp;",
"     </li>",
"     <li>",
"      Serologic tests, which indicate past exposure to pathogens, are useful in the pretransplant setting to assess the presence of latent disease but are not generally useful for acute diagnosis after transplantation.",
"     </li>",
"     <li>",
"      Transplant recipients are particularly vulnerable to organisms resistant to antimicrobial agents either from the hospital environment or through induction of antibiotic resistance in their flora during therapy.",
"     </li>",
"     <li>",
"      When undrained fluid collections, blood, or devitalized tissues are present, antimicrobial therapy alone is inadequate. Early and aggressive surgical debridement of such collections is essential for successful care. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/1\">",
"      Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/2\">",
"      Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995; 21:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/3\">",
"      The AST Infectious Disease Community of Practice, Amercian Society of Transplantation, Infectious Disease Guidelines for Transplantation. Am J Transpl 2009; 9 (Suppl 4):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/4\">",
"      Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010; 24:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/5\">",
"      Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995; 9:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/6\">",
"      Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/7\">",
"      Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/8\">",
"      Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/9\">",
"      Aguado JM, Herrero JA, Gavald&aacute; J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/10\">",
"      Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/11\">",
"      Dubberke ER, Riddle DJ, AST Infectious Diseases Community of Practice. Clostridium difficile in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/12\">",
"      Morris MI, Fischer SA, Ison MG. Infections transmitted by transplantation. Infect Dis Clin North Am 2010; 24:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/13\">",
"      Fishman JA, Greenwald MA, Grossi PA. Transmission of infection with human allografts: essential considerations in donor screening. Clin Infect Dis 2012; 55:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/14\">",
"      Kumar D, Prasad GV, Zaltzman J, et al. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004; 77:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Balamuthia mandrillaris transmitted through organ transplantation --- Mississippi, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: transplant-transmitted Balamuthia mandrillaris --- Arizona, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/17\">",
"      Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006; 354:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Brief report: Lymphocytic choriomeningitis virus transmitted through solid organ transplantation--Massachusetts, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/19\">",
"      Amman BR, Pavlin BI, Albari&ntilde;o CG, et al. Pet rodents and fatal lymphocytic choriomeningitis in transplant patients. Emerg Infect Dis 2007; 13:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/20\">",
"      Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008; 358:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Transplantation-transmitted tuberculosis--Oklahoma and Texas, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/22\">",
"      Aguado JM, Torre-Cisneros J, Fort&uacute;n J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48:1276.",
"     </a>",
"    </li>",
"    <li>",
"     Grady, D. Four transplant recipients contract HIV. New York Times, November 2007. www.nytimes.com/2007/11/13/health/13cnd-organ.html?em (Accessed May 29, 2008.).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Transmission of hepatitis C virus through transplanted organs and tissue--Kentucky and Massachusetts, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: transplant-transmitted hepatitis B virus --- United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/26\">",
"      Zou S, Dodd RY, Stramer SL, et al. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004; 351:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/27\">",
"      van den Berg AP, Klompmaker IJ, Haagsma EB, et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant 1996; 10:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/28\">",
"      George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/29\">",
"      Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/30\">",
"      Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/31\">",
"      Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995; 9:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/32\">",
"      Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/33\">",
"      Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/34\">",
"      Wilck M, Fishman JA. The challenges of infection in transplantation: donor-derived infections. Curr Opin Transpl 2005; 10:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/35\">",
"      Talbot TR, Hatcher J, Davis SF, et al. Scedosporium apiospermum pneumonia and sternal wound infection in a heart transplant recipient. Transplantation 2002; 74:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/36\">",
"      Fishman JA. Vancomycin-resistant Enterococcus in liver transplantation: what have we left behind? Transpl Infect Dis 2003; 5:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/37\">",
"      Bocchi EA, Bellotti G, Mocelin AO, et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg 1996; 61:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/38\">",
"      Centers for Disease Control and Prevention (CDC). Chagas disease after organ transplantation--Los Angeles, California, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/39\">",
"      Fern&agrave;ndez-Sab&eacute; N, Cervera C, Fari&ntilde;as MC, et al. Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study. Clin Infect Dis 2012; 54:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/40\">",
"      Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/41\">",
"      Infectious Disease Community of Practice, Amercian Society of Transplantation, Infectious Disease Guidelines for Transplantation. Amer J Transpl 2004; 4 Suppl 10:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/42\">",
"      Mendez JC, Dockrell DH, Espy MJ, et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/43\">",
"      Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/44\">",
"      Terrault NA, Wright TL, Pereira BJ. Hepatitis C infection in the transplant recipient. Infect Dis Clin North Am 1995; 9:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/45\">",
"      Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 1988; 331:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/46\">",
"      Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/47\">",
"      Gardner SD, MacKenzie EF, Smith C, Porter AA. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol 1984; 37:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/48\">",
"      Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/49\">",
"      Nickeleit V, Hirsch HH, Binet IF, et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol 1999; 10:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/50\">",
"      Singh N, Carrigan DR. Human herpesvirus-6 in transplantation: an emerging pathogen. Ann Intern Med 1996; 124:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/51\">",
"      Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006; 43:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/52\">",
"      Barzon L, Murer L, Pacenti M, et al. Investigation of intrarenal viral infections in kidney transplant recipients unveils an association between parvovirus B19 and chronic allograft injury. J Infect Dis 2009; 199:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/53\">",
"      Falagas ME, Snydman DR, George MJ, et al. Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Transplantation 1996; 61:1716.",
"     </a>",
"    </li>",
"    <li>",
"     Lake KD. Drug interactions in transplant patients. In: Handbook of Cardiac Transplantation, Emery RW, Miller LM (Eds), Hanley and Belfus, Philadelphia 1995. p.173.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/55\">",
"      Venkataramanan R, Habucky K, Burckart GJ, Ptachcinski RJ. Clinical pharmacokinetics in organ transplant patients. Clin Pharmacokinet 1989; 16:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/47/29433/abstract/56\">",
"      Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991; 35:1186.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1396 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-218.28.111.102-E73EFF4BA8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29433=[""].join("\n");
var outline_f28_47_29433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK OF INFECTION FOLLOWING TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiologic exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Community-acquired pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Reactivation of infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nosocomial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Donor-derived infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bloodstream infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inapparent infections accelerated by immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - CMV and EBV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Tuberculosis and histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - HIV, HTLV, and hepatitis viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Net state of immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TIMING OF INFECTION POSTTRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      First month after transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Donor-derived infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Infectious complications related to surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      One to six months after transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      More than six months after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      VIRUSES AS COPATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Direct effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Indirect effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Specific viral pathogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1396|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/33/22035\" title=\"figure 1\">",
"      Infection timeline SOT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1396|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/25/24987\" title=\"table 1\">",
"      Fungal infx in transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/9/33948\" title=\"table 2\">",
"      Infection exclusion organ donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/19/2364\" title=\"table 3\">",
"      Donor derived infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/19/316\" title=\"table 4\">",
"      Immunosuppressive rx infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/55/6012\" title=\"table 5\">",
"      Common viral infections in SOT recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/12/16588\" title=\"table 6\">",
"      CMV effects in transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=related_link\">",
"      Disease associations of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=related_link\">",
"      Evaluation for infection before hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14201?source=related_link\">",
"      Human herpesvirus 7 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=related_link\">",
"      Infectious complications in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=related_link\">",
"      Viral load testing for cytomegalovirus in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=related_link\">",
"      Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_47_29434="Nonatrophic gastritis";
var content_f28_47_29434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Non-atrophic active gastritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 541px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mononuclear leukocytes (arrowhead) infiltrate the stroma. The gastric glands are well preserved. Polymorphonuclear leukocytes (arrow) infiltrate the epithelial lining.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29434=[""].join("\n");
var outline_f28_47_29434=null;
var title_f28_47_29435="Classification of allergic rhinitis";
var content_f28_47_29435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F85849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F85849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of allergic rhinitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        \"Intermittent\" means that the symptoms are present:",
"        <ul>",
"         <li>",
"          Less than&nbsp;four days a week",
"         </li>",
"         <li>",
"          Or for less than&nbsp;four weeks",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Persistent\" means that the symptoms are present:",
"        <ul>",
"         <li>",
"          More than&nbsp;four days a week",
"         </li>",
"         <li>",
"          And for more than&nbsp;four weeks",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Mild\" means that none of the following items are present:",
"        <ul>",
"         <li>",
"          Sleep disturbance",
"         </li>",
"         <li>",
"          Impairment of daily activities, leisure and/or sport",
"         </li>",
"         <li>",
"          Impairment of school or work",
"         </li>",
"         <li>",
"          Troublesome symptoms",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Moderate-severe\" means that one or more of the following items are present:",
"        <ul>",
"         <li>",
"          Sleep disturbance",
"         </li>",
"         <li>",
"          Impairment of daily activities, leisure and/or sport",
"         </li>",
"         <li>",
"          Impairment of school or work",
"         </li>",
"         <li>",
"          Troublesome symptoms",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:S147. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29435=[""].join("\n");
var outline_f28_47_29435=null;
var title_f28_47_29436="Indications for VFA";
var content_f28_47_29436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for vertebral fracture assessment (VFA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Postmenopausal women with low bone mass (osteopenia) by BMD criteria, PLUS any one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age greater than or equal to 70 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Historical height loss greater than 4 cm (1.6 in)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prospective height loss greater than 2 cm (0.8 in)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-reported prior vertebral fracture (not previously documented)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two or more of the following:",
"        <br/>",
"        <ul>",
"         <li>",
"          Age 60 to 69 years",
"         </li>",
"         <li>",
"          Self-reported prior non-vertebral fracture",
"         </li>",
"         <li>",
"          Historical height loss of 2 to 4 cm",
"         </li>",
"         <li>",
"          Chronic systematic diseases associated with increased risk or vertebral fractures (for example, moderate to severe COPD or COAD, seropositive rheumatoid arthritis, Crohn's disease)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Men with low bone mass (osteopenia) by BMD criteria, PLUS one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age 80 years or older",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Historical height loss greater than 6 cm (2.4 in)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prospective height loss greater than 3 cm (1.2 in)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-reported vertebral fracture (not previously documented)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two or more of the following:",
"        <br/>",
"        <ul>",
"         <li>",
"          Age 70 to 79 years",
"         </li>",
"         <li>",
"          Self-reported prior non-vertebral fracture",
"         </li>",
"         <li>",
"          Historical height loss of 3 to 6 cm",
"         </li>",
"         <li>",
"          On pharmacologic androgen deprivation therapy or following orchiectomy",
"         </li>",
"         <li>",
"          Chronic systemic diseases associated with increased risk of vertebral fractures (for example, moderate to severe COPD or COAD, seropositive rheumatoid arthritis, Crohn's disease)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Women or men on chronic glucocorticoid therapy (equivalent to 5 mg or more of prednisone daily for three months or longer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Postmenopausal women or men with osteoporosis by BMD criteria, if documentation of one or more vertebral fractures will alter clinical management",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BMD: bone mineral density; COPD: chronic obstructive pulmonary disease; COAD: chronic obstructive airways disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: the 2007 International Society for Clinical Densitometry Official Positions. Full report available at:",
"     <a href=\"file://www.iscd.org/visitors/positions/OfficialPositionsText.cfm\" target=\"_blank\">",
"      file://www.iscd.org/visitors/positions/OfficialPositionsText.cfm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29436=[""].join("\n");
var outline_f28_47_29436=null;
var title_f28_47_29437="Diabetogenic genes";
var content_f28_47_29437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Association of type 1 diabetes with diabetogenic genes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct correlation in different populations between the gene frequency of \"diabetogenic\" HLA-DQ&beta; genotypes (which lack aspartate at position 57 on the beta chain) and the predicted and observed incidence of type 1 diabetes mellitus (per 100,000 population).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dorman JS, LaPorte RE, Stone RA, Trucco M,&nbsp;Worldwide differences in the incidence of type I diabetes are associated with amino acid variation at position 57 of the HLA-DQ beta chain. Proc Natl Acad Sci USA 1990; 87:7370.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29437=[""].join("\n");
var outline_f28_47_29437=null;
var title_f28_47_29438="Xerocytosis flow cytometry";
var content_f28_47_29438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow cytometry studies in Hereditary xerocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 484px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distribution histograms for red blood cell volume (mean corpuscular volume) and mean cell hemoglobin concentration in a normal control (top) and a patient with hereditary xerocytosis (bottom). Hereditary xerocytosis is characterized by a shift of the mean corpuscular (red cell) volume to higher values, which is indicative of the presence of reticulocytes and younger cells, and of the mean cell hemoglobin concentration to higher values, which is indicative of the presence of hyperchromic cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carlo Brugnara, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29438=[""].join("\n");
var outline_f28_47_29438=null;
var title_f28_47_29439="MCT flowchart";
var content_f28_47_29439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Methacholine challenge testing sequence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 657px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The choice of the FEV1 value considered a contraindication may vary from 60 to 70 percent of predicted.",
"     <br>",
"      &bull; The final dose may vary depending on the dosing schedule used. Final doses discussed in this statement are 16, 25 and 32 mg/mL.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_47_29439=[""].join("\n");
var outline_f28_47_29439=null;
